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Pork is the most widely consumed type of meat worldwide. In 2019 the average German per 
capita pork consumption was 36kg which represents 60% of total meat consumption [1]. Large 
scale animal farming and climate change put increasing demands on animal health which is 
highly influenced by genetic factors [2, 3]. Gene editing (GE) could complement traditional 
livestock breeding to improve animal welfare. Due to similarities in size and physiology to 
humans, the pig has gained significance as a model organism in biomedicine besides its 
important role in agriculture [4, 5]. These traits make the pig a suitable model organism to 
investigate the risks and side effects of GE and generate significant data for potential 
agricultural and therapeutic applications.  
The goal of this work was to evaluate the feasibility, efficiency, and safety of GE in pigs. 
Oedema disease (OD) was chosen as the target for GE due to its global significance regarding 
animal welfare and economics. OD is caused by E. coli F18 bacteria that bind to the intestinal 
mucosa and produce Shiga toxin 2e (Stx2e) which causes oedema and central nervous system 
dysfunction [6]. The respective receptor is synthesised by the enzyme -1,2 fucosyltransferase 
encoded by the FUT1 gene [7, 8]. One gene variant leads to an amino acid exchange (p.T103A). 
The FUT1-AA genotype leads to a loss of fucosyl structures on the receptor which prevents E. 
Coli F18 binding and thereby mediates OD resistance [9]. Gene editing could be used to 
increase the incidence of the favourable FUT1 variant within the breeding population. 
The second part of this work focuses on investigating the frequency of off-target mutations 
caused by CRISPR/Cas9, the most widely used GE tool. Concerns regarding the safety of this 
technology, particularly the potential for inducing off-target mutations prevent its more 
widespread application [10]. Off-target analysis is typically performed by screening in silico 
predicted off-target sites or by whole genome sequencing [11]. The fundamental problem with 
these approaches is that single nucleotide variants (SNVs) that occur during embryogenesis 
cannot be distinguished from mutations caused by GE technology [12].  
The aim of this study was to analyse the frequency at which the CRISPR/Cas9 system generates 
off-target mutations in vivo using a novel approach termed genome-wide off-target analysis by 
two-cell embryo injection (GOTI). This method is based on the generation of mosaic foetuses 
containing edited and non-edited cells by microinjection of CRISPR/Cas9 expression vectors 




sequenced to determine the mutation frequency and off-target sites. The non-edited cells are 
the best possible control group because both cell populations stem from the same embryo [12].  
The GGTA1 gene which encodes the enzyme -1,3-galactosyltransferase  was chosen as the 
target for gene editing because its inactivation leads to a loss of the -1,3-Gal glycosylation 
[13]. The presence or absence of this cell surface epitope facilitates the precise separation of 
edited and non-edited cell populations [14]. For the first time, this proof-of-principle 
experiment provides comprehensive insights regarding off-target events in livestock species 
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2.1. Oedema Disease 
 
2.1.1. Clinical Signs and Lesions 
 
Oedema Disease is an enterotoxaemia that mainly occurs in healthy, rapidly growing pigs seven 
to ten days after weaning [15]. OD epidemics characteristically begin and end suddenly on 
average lasting less than eight days [16]. Morbidity rates of 30-40% are coupled with high 
mortality rates up to 90% [17]. Enzootic persistence frequently leads to the recurrence of the 
disease within affected populations [18].  
The main clinical signs of OD are oedema and dysfunction of the central nervous system (CNS) 
which reflect vascular damage. Acute cases are characterised by constipation and subcutaneous 
oedema typically in the eyelids and abdomen (see Figure 1) [19]. The progressive loss of CNS 
function leads to staggering gait followed by complete paralysis, lateral recumbency, dyspnoea, 
and generalised muscle tremors [20]. Death usually occurs one to three days after onset of 
symptoms and within 24 hours if neurological symptoms arise [21]. Subacute and chronic cases 
of OD result in decreased weight gain and therefore lower slaughter weight [22]. Peracute OD 
is characterised by sudden death without any preceding signs of illness [21]. Other possible 
pathological findings include haemorrhagic necrosis of intestinal mucosa, hydropericardium, 
pulmonary oedema, and altered vocal expression due to laryngeal oedema [23]. 
 
Figure 1: Typical clinical signs of OD. A) Periocular oedema and B) Oedema in the submucosa of the stomach 
and mesocolon (from Swine Disease Manual 4th Edition Ed. Neumann [24]). 
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Microscopically, degenerative angiopathy of small arteries and arterioles can be observed [20]. 
Fibrinoid necrosis of the smooth muscle cells in the tunica media is accompanied by 
perivascular haemorrhage [25]. This severe vascular damage causes microthrombus formation, 
infarction, and perivascular oedema resulting in ischaemic necrosis of the surrounding 
parenchyma [26]. These vascular lesions are most prominent in the brain stem, intestine, and 
kidneys. Focal encephalomalacia and infarction of the brain stem is characteristic and the main 
cause of death among affected pigs [20]. 
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2.1.2. Aetiology and Pathogenesis 
 
OD is caused by pathogenic serogroups of Escherichia coli (E. Coli) that produce Shiga toxin 
2e (Stx2e) [6]. Stx2e is absorbed into the bloodstream from the intestine and binds to the 
vascular endothelium, inhibits protein synthesis, and causes cell death which leads to the 
characteristic vascular lesions (see Figure 2) [27]. The causal relationship between Stx2e and 
OD has been confirmed through intravenous injection of Stx2e which exactly replicates the 
microscopic lesions and symptoms of OD [28]. Some serotypes of E. Coli also produce 
enterotoxins which cause severe diarrhoea in addition to the usual symptoms of OD [29, 30].  
Adhesion to the intestinal mucosa is mediated by F18ab fimbriae that bind to the E. Coli F18 
receptor (ECF18R) located on the membrane of enterocytes [31]. During the acute phase of 
infection up to 109 colony forming units (CFU) of E. Coli per cm2 can be found in the small 
intestine of pigs [32].  
The initial source of infection is usually the sow or contaminated environment [26]. The decay 
of maternal antibodies and stress associated with the sudden change in diet and mixing of the 
pigs are responsible for the high susceptibility of pigs in the post-weaning period [33]. A highly 
nutritious and energy-rich diet is another predisposing factor for OD [6]. This explains the high 
incidence of OD especially among the fastest-growing pigs in intensive large-scale animal 
farming facilities [34]. 
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Figure 2: Pathogenesis of OD. Pathogenic E. Coli are orally ingested, proliferate in the intestine, and produce 
Stx2e Shiga toxin which damages the capillaries and causes the typical symptoms of OD (from “Disease of Swine” 
11th edition [35]). 
 
A single (G>A) nucleotide polymorphism (SNP) at base pair (bp) 307 of the α-1,2- 
fucosyltransferase (FUT1) gene located on the porcine Chromosome 6 controls F18ab mediated 
binding of E. Coli [7, 8]. Resistance and susceptibility to OD are thus determined by a single 
recessively inherited gene variant at a particular genomic locus [9]. The prevalence of the 
resistant FUT1-AA genotype within the pig population is breed specific and ranges from 6% in 
German Landrace (GL), 25% in Piétrain (PI) up to 75% in Large White (LW) [36]. OD resistant 
individuals in the pig population can be detected by Polymerase Chain Reaction (PCR) and 
then used for breeding [37]. There are concerns about selecting for OD resistance because this 
genotype was shown to be correlated with susceptibility to Porcine Stress Syndrome (PSS) in 
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2.1.3. Diagnosis and Treatment  
 
The characteristic set of neurological symptoms and its occurrence in a specific age group make 
typical outbreaks of OD easy to diagnose. Differential diagnoses are Pseudorabies (Aujeszky’s 
disease), meningitis (usually Streptococcus suis), Glasser’s Disease (Haemophilus parasuis), 
and water deprivation [40]. Isolation and characterisation of E. Coli is the standard procedure 
for a definitive diagnosis but can be difficult as the pathogen is often absent by the time of death 
[26]. Detection and quantification of virulence factors like F18ab fimbria and Stx2e by 
quantitative PCR is a sensitive and specific method to diagnose OD [31, 41]. 
Due to the sudden onset and rapid course of OD disease prevention is more effective than 
treatment [42]. Reducing the energy content of feed after weaning decreases the incidence of 
OD regardless of fibre and protein content. However, these dietary measures impair growth and 
weight gain before reaching significant clinical efficacy [34]. Pre-emptive administration of 
antibiotics in the post-weaning period is another effective measure to prevent OD. However, 
this approach has potential for the selection of strains with antimicrobial resistance and prevents 
active immunisation [43]. Immunisation against Stx2e and F18ab is another effective but costly 
control strategy. A variety of vaccines has been developed for this purpose including inactivated 
Stx2e toxoid, non-toxigenic F18ab E. Coli, and passive vaccination with F18ab antibodies [42, 
44, 45].  
Selective breeding for OD resistance is another control strategy that has proven to be effective 
in reducing the incidence of OD in breeding populations when systematically implemented [6, 
7]. The low prevalence of the resistant gene variant in certain breeds makes this approach hard 
to realise without compromising genetic diversity and long-term productivity [7, 36]. Similarly, 
the incorporation of the OD resistant gene variant from other breeds and related species by trait-
selective breeding is likely to result in a loss of productivity regarding other desired 
performance parameters [46]. Several studies have highlighted the potential of gene editing to 
incorporate genetic traits into productive, genetically diverse animals [39, 46, 47]. For example, 
GE technology has already been used to generate Porcine Reproductive and Respiratory 
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2.2. Off-Target Effects in CRISPR/Cas9 mediated Gene 
Editing 
 
2.2.1. The CRISPR/Cas9 System 
 
The clustered regularly interspaced short palindromic repeat (CRISPR) / CRISPR associated 
nuclease (Cas) system was originally discovered as part of the adaptive immune system in 
archaea and bacteria [49]. CRISPRs are short, repeating sequences of viral DNA that are 
integrated into the bacterial genome and function as an immunological memory system in 
prokaryotes [50]. Upon reinfection, transcripts of these repeats guide the Cas endonuclease to 
the complementary sequence of the pathogen and induce DNA double strand breaks (DSBs) 
[51]. Three types of CRISPR systems are known in prokaryotes but only the CRISPR type II 
system which includes CRISPR associated nuclease 9 (Cas9) has been adapted for GE (see 
Figure 3) [52, 53]. The implementation of the CRISPR/Cas system for GE in mammalian cells 
requires only three components: Cas9, CRISPR RNA (crRNA) and transactivating crRNA 
(tracrRNA) [54, 55]. CrRNA and tracrRNA form an RNA complex that guides Cas9 to the 
target sequence [55]. For GE purposes this complex has been replaced with a synthetic single 
guide RNA (sgRNA) [56]. The first 20 nucleotides of the sgRNA determine the target DNA 
sequence. They can be adapted to recognize any target sequence with a subsequent 3’ “NGG” 
protospacer adjacent motif (PAM) [51, 57]. Targeting of multiple genetic loci is enabled by 
applying several different sgRNAs simultaneously [58]. 
 
Figure 3: The CRISPR/Cas9 system as a tool for genome engineering. The 20bp sgRNA which determines the 
target sequence is connected to the tracrRNA with a linker loop to form a sgRNA (adapted from Jinek et al. [56]). 
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Upon recognition of the target site, Cas9 induces a double-strand break (DSB) which activates 
the cell’s intrinsic DNA repair mechanisms, such as non-homologous end joining (NHEJ) and 
homology directed repair (HDR) (see Figure 4) [51, 59]. The repair of DSBs by NHEJ 
frequently causes insertions or deletions (indel mutations) which disrupt regulatory elements or 
lead to frameshift mutations in coding regions and gene inactivation [60]. In HDR DSBs are 
repaired consulting homologous sequences to facilitate accurate repair [61]. By providing DNA 
donor templates flanked with sequences homologous to the target site HDR can be utilised for 
the targeted integration of exogeneous DNA [62, 63]. 
 
Figure 4: Repair of DSBs through HDR or NHEJ. NHEJ frequently leads to indel mutations causing frameshift 
and thus the inactivation of the target gene. By providing DNA donor templates with homologous arms to the 
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2.2.2. Off-Target Mutations 
 
Its high efficiency, cost-effectiveness, accuracy, and ease of use have made CRISPR/Cas the 
most widely used GE technology worldwide [64, 65]. The CRISPR/Cas system has been used 
to successfully generate GE plants, livestock, and humans [66-68]. However, the potential for 
the introduction of off-target mutations that could result in adverse phenotypic consequences 
limits the use of GE technology [69].  
The specificity of the CRISPR/Cas9 system is tightly determined by the 20 nucleotides long 
sgRNA sequence followed by the presence of the PAM site in the genome [70]. The sgRNA 
can be subdivided into the 5’ non-seed sequence and the 10 to 12 bp long 3’ PAM proximal 
seed sequence [71]. Recent findings suggest that the seed region comprises only three to five 
bp adjacent to the PAM motif [72]. The seed sequence is critical in determining the specificity 
of the gRNA as correct sequence alignment next to the PAM is essential for DNA targeting [73, 
74]. Off-target cleavage can however occur in regions with up to 5 base pair mismatches from 
the target site in the 5’ non-seed segment of the sgRNA [75]. The frequency at which a region 
complementary to the respective “seed + PAM” sequence exists in the genome determines 
specificity [76]. U-rich seed sequences can induce the termination of transcription and can 
therefore result in increased specificity [72]. SgRNAs with very high or low GC content in the 
seed sequence lead to reduced activity of the CRISPR/Cas9 system [77]. The length of the 
sgRNA influences targeting efficiencies and the frequency of off-target mutations [81, 82]. 
Other than the usual NGG the CRISPR type II system also recognise NAG as a PAM sequence 
[75]. However, the design of CRISPR/Cas9 sequences using a NAG PAM reportedly reduces 
binding specificity by up to 80% compared to an NGG PAM [78, 79]. 
The way of application of the CRISPR/Cas9 system plays an important role in the generation 
of off-target effects. Delivery of Cas9 protein and sgRNA as ribonucleoprotein (RNP) 
complexes facilitate genome editing without requiring transcription and translation resulting in 
faster cleavage of the target sequence [80]. RNP complexes are degraded quickly after they 
cleave the target sequence which reduces the number of off-target mutations compared to the 
utilisation of plasmids encoding both components [81].  
The frequency of off-target mutations is linked to the integrity of the cell’s internal DNA repair 
pathways and therefore highly cell-type dependant [82]. The frequency of off-target mutations 
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is relatively high in cancer cells [83]. However, there is a scientific consensus that in cells with 
intact DNA repair pathways CRISPR/Cas9 technology causes very few off-target mutations 
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2.2.3. Detection of Off-Target Mutations 
 
Comprehensive and sensitive detection and quantification of off-target mutations remains a 
major challenge [86]. Methods for the identification of off-target mutations can be categorised 
as in silico prediction tools, sequencing-based in vitro methods, and in vivo methods [87].  
 
2.2.3.1. In silico prediction tools 
 
The most common method for off-target analysis in the literature is the screening of in silico 
predicted off-target sites. A variety of algorithms and web-based tools such as CRISPOR 
(http://crispor.org), CCTop (http://crispr.cos.uni-heidelberg.de) and Cas-OFFinder 
(http://www.rgenome.net/cas-offinder/)  have been developed for this purpose [88-90].  
These tools predict potential off-target sites based on the number and location of mismatches 
compared to the target site. One built-in limitation of this approach is that it neglects off-target 
sites with less sequence similarity [91]. Furthermore, all algorithms rely on the availability of 
a high-quality reference genome for each specific species and genotype [92]. Overall, in silico 
tools can identify potential off-target sites but currently still fail to accurately predict in vivo 
mutations [75, 93]. 
Another field of application for prediction algorithms is to facilitate the design of sgRNAs that 
minimise potential off-target mutations [87]. Several tools such as CRISPR-P2.0 
(http://cbi.hzau.edu.cn/CRISPR2), E-CRISP (http://www.e-crisp.org) and Breaking-Cas 
(http://bioinfogp.cnb.csic.es/tools/breakingcas) were developed specifically to aid the design of 
sgRNAs for GE [94-96].  
 
2.2.3.2. In vitro methods 
 
There is a wide spectrum of in vitro methods for the detection and quantification of off-target 
mutations that each have their individual benefits and drawbacks. The following segment 
describes the most relevant methods. 
The first valid method for the detection of off-target mutations was the T7 endonuclease I 
(T7E1) assay [97]. This assay utilises the ability of T7E1 to recognise single bp mismatches 
13 
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and cut DNA at the respective site. In case a wild-type DNA strand binds to a mutated one they 
form a heteroduplex at the mismatched site which can be recognised by T7E1 [98]. The 
resulting DNA fragments can be detected by gel electrophoresis. Drawbacks to this approach 
are its poor sensitivity and high cost [98, 99]. 
Whole genome sequencing (WGS) is an unbiased and comprehensive method for the 
assessment of off-target mutations [100]. Mutations are detected by WGS of cells prior to and 
after GE followed by comparison to the unedited control group. Precise investigation of the 
genetic background is critical for this approach [101]. WGS has been used for the detection of 
off-target mutations in a variety of plants and mammalian species [69, 84, 87]. WGS is suited 
for the analysis of single cells and genome-edited animals but lacks the sensitivity required for 
the detection of low-frequency off-target mutations in cell pools [84]. Similar to other methods, 
the screening of off-target effects via WGS found the frequency of mutations caused by 
CRISPR/Cas9 technology to be relatively low [85]. However, WGS cannot distinguish single 
nucleotide variants (SNVs) caused by GE from those that occur naturally or are caused by 
sequencing errors [12, 87]. 
Genome-Wide, Unbiased Identification of DSBs enabled by Sequencing (GUIDE-Seq) 
facilitates the  genome-wide analysis of off-target mutations based on the integration of tagged 
DNA fragments into DSB breaks followed by their amplification and sequencing [102]. 
GUIDE-Seq is very sensitive and can detect off-target mutations that occur at frequencies as 
low as 0,12%. However, GUIDE-Seq requires the integration of additional exogeneous DNA 
which can affect gene editing outcomes and is inefficient in primary cells [103]. 
CIRCLE-Seq is another method for the genome-wide identification of off-target mutations  
[104]. CIRCLE-Seq is based on next generation sequencing technology and excels at the 
detection of cell-type-specific SNPs [105]. CIRCLE-Seq does not require a reference genome 
which allows the detection of off-target mutations in species where the full genomic sequence 
is not available [104].   
Digested Genome Sequencing (Digenome-Seq) is an unbiased and cost-effective method for 
the detection of off-target mutations [106]. Digenome-Seq is a two-step process in which 
genomic DNA is isolated from modified cells and a control group followed by in vitro digestion 
and WGS. The resulting DNA fragments are aligned and compared to the reference genome to 
detect on- and off-target cleavage sites [106]. Digenome-Seq can detect off-target mutations 
that occur at frequencies as low as 0.1% [107]. Its high sensitivity and the fact that it is based 
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on DNA cleavage rather than the integration of exogeneous DNA make Digenome-Seq the gold 
standard to evaluate the specificity of GE tools at the time of writing [87, 91]. 
 
2.2.3.3. Detection of off-target mutations in vivo 
 
In vitro methods are highly sensitive at detecting off-target mutations but fail to accurately 
predict mutations that occur in vivo [75, 98, 108]. The scientific literature suggests that off-
target mutations occur at much lower frequencies in vivo compared to in vitro experiments. 
Animal experiments in mice [109, 110], pigs [66], and monkeys [111, 112] have not revealed 
any off-target mutations at the predicted off-target sites so far. However, in most publications 
off-target detection has been limited to the screening of in silico predicted off-target sites [91, 
100]. Comprehensive, sensitive, unbiased screening of off-target mutations at the animal level 
is necessary to evaluate the target specificity of CRISPR/Cas9 and other GE tools in vivo [113]. 
The two most relevant methods for this purpose are described in this paragraph. 
Verification of in vivo off-targets (VIVO) is a sensitive method for the genome-wide detection 
of off-target mutations in vivo [114]. VIVO utilises CIRCLE-Seq to identify potential off-target 
cleavage sites followed by the in vivo examination of target tissues for indel mutations. VIVO 
facilitates the detection and quantification of off-target mutations within whole organisms [87]. 
It has been used to confirm in vivo GE in mice using CRISPR/Cas technology without 
detectable off-target mutations [114]. 
Genome-wide off-target analysis by two-cell embryo injection (GOTI) is an approach for the 
evaluation of off-target mutations in a cell population derived from a single GE blastomere 
[12]. GOTI was conducted in mouse embryos by editing one blastomere of two-cell embryos 
and then comparing the whole genome sequence of cells derived from edited and non-edited 
blastomeres (see Figure 5) [12].  
 
 
Figure 5: Experimental design of GOTI. CRISPR-Cas9 or base editors together with Cre mRNA are injected into 
one blastomere of two-cell embryos derived from LoxP-Stop-LoxP-tdTomato mice. Edited and non-edited cells 
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are separated, sorted by FACS based on tdTomato expression followed by WGS and analysis of Indels and SNVs 
(from Zuo et al. [12]). 
 
The distinguishing feature of this method is that it facilitates the evaluation of off-target 
mutations caused by GE tools without the interference of SNPs present in distinct individuals 
[115]. GOTI revealed the frequency of off-target SNPs in embryos edited by CRISPR/Cas9 or 
adenine base editors to be close to the spontaneous mutation rate whereas cytosine base editors 
induced SNPs 20 times more frequently [12]. These findings are however limited to mouse 
embryos because so far, no data for non-rodent species has been published.  
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2.2.4. Minimising off-target effects 
 
There are various strategies to reduce the incidence of off-target effects caused by 
CRISPR/Cas9 technology [106].  
First, off-target mutations can be reduced by decreasing the concentration of CRISPR/Cas9 
components i.e., Cas9 and sgRNA but this approach also reduces on-target cleavage efficiencies 
[116]. Therefore,  a compromise between efficient on-target cleavage and the reduction of off-
target mutations is inevitable. 
Shorter tissue culture time can reduce off-target mutations by lowering the duration of nuclease 
expression and thereby the risk for the accumulation of off-target mutations [117]. Delivering 
the components of the CRISPR/Cas9 system as Cas9 protein or mRNA together with the 
sgRNA can reduce off-target mutations compared to DNA GE vectors encoding both 
components [107, 118].  
Optimal sgRNA design can further improve Cas9 specificity [78]. Several online tools have 
been developed specifically to design optimal sgRNA sequences (see 2.3.1.) [94-96]. Truncated 
small sgRNAs with shorter complementary regions to the target site (17-18bp) can further 
reduce undesired mutations [119]. 
CRISPR/Cas9 technology is rapidly evolving and a variety of modified Cas9 variants with high 
fidelity have been developed. Such optimised Cas9 variants include Base Editing [120], 
Nickases [121], Prime Editing [122], SpCas9-HF1 [123], eSpCas9 [124] and HypaCas9 [125]. 
Base editing is an approach that converts specific bases into another utilising a deaminase 
enzyme fused to an inactive Cas9 protein [126]. This method does not require the generation of 
DBS which theoretically should decrease the occurrence of off-target mutations [120]. 
However, base editors were shown to generate considerable off-target SNPs in vitro and in vivo 
[12, 127]. 
Nickases are another modification to the CRISPR system that causes single strand DNA breaks 
[121]. The so-called 'double nicking' approach uses paired Nickases guided by two sgRNAs to 
generate DSBs with high precision which increases specificity compared to the original version 
[128]. The frequency of off-target mutations can be further reduced by combining 'double 
nicking' with truncated sgRNAs [128].  
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'Prime editing' is a new approach that uses a reverse transcriptase enzyme connected to a 
catalytically inactive Cas9. The target site plus the intended modification are both specified by 
a prime editing gRNA. First reports claim high efficiencies and reduced off-target effects with 
this method [122]. 
SpCas9-HF1 is a Cas9 variant specifically designed to improve specificity [123]. SpCas9-
HF1’s on-target activity is comparable to SpCas9, but nonspecific DNA interactions are greatly 
reduced [123]. Similarly, eSpCas9 is an optimised Cas9 nuclease that was rationally designed 
via structure-guided protein engineering to improve specificity [124]. The HypaCas9 system 
offers higher genome-wide fidelity combined with precise on-target genome editing [125].  
In summary,  GE technology is evolving at a rapid pace and more accurate, efficient, and 
reliable tools are developed at a fast pace. 
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Genome engineering could complement traditional breeding techniques to enhance the 
potential of the pig for agriculture and biomedical research. However, the safety and accuracy 
of this approach must be confirmed prior to its practical implementation.  
 
The main goal of this project was to establish and evaluate methods for precise, efficient, and 
safe CRISPR/Cas9 mediated gene editing in pigs using the example of Oedema disease. This 
entails the design and optimisation of Cas9 vectors and repair templates to edit the FUT1 gene 
in vitro in somatic cells and in vivo in porcine embryos. The generation of genetically modified 
animals was not planned in this project.  
 
The objective for the second part of this work was to precisely investigate the frequency at 
which CRISPR/Cas9 technology causes off-target mutations. For this purpose, mosaic foetuses 
were to be generated by microinjection of gene editing vectors into one blastomere of porcine 
two-cell-stage embryos. The next goal was to separate the edited and non-edited cells and 
perform whole genome sequencing to distinguish off-target mutations from single nucleotide 
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Accu-jet pro Brand, Dietenhofen, GER 
Blue light table Serva, Heidelberg, GER 
Bunsen burner “Gasprofi 2“ WLD-TEC GmbH, Arenshausen, GER 
Camera AxioCam MR (Axiovision) Carl Zeiss Jena GmbH, Jena, GER 
Centrifuge „Sigma 3-16KL “ Sigma, Osterode, GER 
Dry block heater “PCH-2” Grant instruments, Royston, GBR 
Electrophoresis system  Peqlab Biotechnologie, Erlangen, GER 
Electroporation cuvettes Peqlab Biotechnologie, Erlangen, GER 
Electroporator: BTX ECM 830  BTX, Holliston, MA, USA 
Flow cytometer “FACSCalibur” BD Bioscience, Franklin Lakes, USA 
Freezer -20°C: “GS 2481“ Liebherr, Bulle, SUI 
Freezer -80°C: “Forma 900 Series “ Thermo Fisher Scientific, Waltham, MA, USA 
Gel documentation imaging system 
“Quantum ST5” 
Vilber Lourmat, Eberhardzell, GER 
Gel electrophoresis chamber Bio-Rad Laboratories GmbH, Munich, GER 
Glasware Marienfeld GmbH, Landa, GER 
Heating plate HT 200 Minitube, Tiefenbach, GER 
Hera Safe clean bench Heraeus Instruments, Hanau, GER 
Ice machine Manitowoc Ice, Manitowoc, WI, USA 
Incubator (Heracell VioS 160i) Thermo Fisher Scientific, Waltham, MA, USA 
Incubator Steri-cycle CO2 Thermo Fisher Scientific, Waltham, MA, USA 
Magnet „Dynamag 15“ Life Technologies, Carlsbad, USA 
Magnetic stirrer “AREC_X” VELP Scientific, Usmate, ITA 
Microinjector: CellTram pro Eppendorf, Hamburg, GER 
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Microscope “Axiovert 40CLF”,  Carl Zeiss GmbH, Jena, GER 
Microwave “MW17M70G-AU” MDA Haushaltswaren, Barsbüttel, GER 
Mr. Frosty freezing container Thermo Fisher Scientific, Waltham, MA, USA 
Neubauer cell counting chamber Brand GmbH, Wertheim, GER 
Orbital shaker Thermo Fisher Scientific, Waltham, MA, USA 
P97-micropipette puller Sutter Instrument, CA, USA 
PCR cycler “PeqStar” Peqlab Biotechnology, Erlangen, GER 
Pipettes “Pipetman “2ul, 20ul, 1000ul” Gilson, Middleton, WI, USA 
Power supply EC105 Electron GmbH, Dreieich, Germany 
Refrigerator “TSE1283” Beko, Neu-Isenburg, GER 
Safety Workbench Hera safe class 2H Heraeus Instruments, Munich, GER 
Stereomicroscope Stemi 508 Carl Zeiss, Göttingen, Germany 
Table centrifuge Sigma-Aldrich GmbH, Steinheim, GER 
Thermos container Alfi GmbH, Wertheim, GER 
Transfer man NK2 micromanipulator Eppendorf, Hamburg, GER 
Transportable incubator Minitube, Tiefenbach, GER 
Vortex mixer “Vortex Genie 2” Scientific industries, Bohemia, NY, USA 




Borosilicate glass with filament  Sutter Instruments, CA, USA 
Cover slips (24x60mm) Menzel, Braunschweig, GER 
Cryo-vials Corning Inc., Corning, NY, USA 
Electroporation cuvettes (2mm, 4mm) Peqlab Biotechnology, Erlangen, GER 
FACS 96-well plates Sarstedt, Nürnbrecht, GER 
Filter pipette tips Fisher Scientific, Hampton, NH, USA 
Gas cylinders (CO2, N2, O2) Westfalen AG, Münster, GER 
IVF 4-well plates Fisher Scientific, Waltham, MA, USA 
Pasteur pipettes Brand, Wertheim, GER 
PCR tubes Starlab, Hamburg, GER 
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Petri dishes Greiner Bio-One, Frickenhausen, GER 
Plastic pipettes „Costar Stripette“(1-50ml) Corning Inc., Corning, NY, USA 
Syringes BD Bioscience, Le Pont De Claix, FRA 
Tissue culture flasks (T25, T75, T150) Corning Inc., Corning, NY, USA 
Tissue culture plates (6-, 12-, 24-well) Corning Inc., Corning, NY, USA 
Tubes (15ml, 50ml) Corning Inc., Corning, NY, USA 





Agarose Sigma-Aldrich, Steinheim, GER 
BSA (fraction V) Biomol, Hamburg, GER 
Calcium chloride (CaCl2) Sigma-Aldrich, Steinheim, GER 
CutSmart Buffer New England Biolabs, Ipswich, USA 
Cysteine Sigma-Aldrich, Steinheim, GER 
Deoxynucleotide solution New England Biolabs, Frankfurt, GER 
Dimethyl-sulfoxide (DMSO) Sigma-Aldrich, Steinheim, GER 
Dynabeads biotin binder Thermo Fisher, Waltham, MA, USA 
Ethanol (EtOH) Fisher Scientific, Loughborough, GBR 
Ethylene diamine tetra-acetic acid (EDTA) AppliChem, Darmstadt, GER 
Foetal calf serum (FCS) PAA laboratories, Pasching, Austria 
Gel loading dye New England Biolabs, Frankfurt, GER 
Glucose (C6H12O6) Sigma-Aldrich, Steinheim, GER 
Glutamine Invitrogen GmbH, Darmstadt, GER 
Glycerol (C3H8O3) AppliChem, Darmstadt, GER 
HEPES buffer Sigma-Aldrich, Steinheim, GER 
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Isolectin B4 (biotin conjugate)  Enzo Life Sciences, Lörrach, GER 
MgSO4 Sigma-Aldrich, Steinheim, GER 
Mineral oil Sigma-Aldrich, Steinheim, GER 
Penicillin-Streptomycin Sigma-Aldrich, Steinheim, GER 
PeqGREEN  VWR International, Ismaning, GER 
PE-streptavidin BD Bioscience, St. Jose, USA 
Phosphate buffered saline (PBS) Sigma-Aldrich, Steinheim, GER 
Polysorbat 20 Sigma-Aldrich, Steinheim, GER 
Polyvinyl alcohol (C2H4O) Sigma-Aldrich, Steinheim, GER 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, Steinheim, GER 
Sodium chloride (NaCl) Sigma-Aldrich, Steinheim, GER 
Sodium hydroxide (NaOH) Sigma-Aldrich, Steinheim, GER 
Sodium pyruvate Sigma-Aldrich, Steinheim, GER 
Tris-HCL Sigma-Aldrich, Steinheim, GER 
Triton X100 Omnilab-Laborzentrum, Bremen, GER 




GoTaq G2 DNA polymerase Promega, Mannheim, GER 
DNA Polymerase I (Klenow Fragment) New England Biolabs, Ipswich, USA 
Hyaluronidase Sigma-Aldrich, Steinheim, GER 
Proteinase K (20mg/ml) Sigma-Aldrich, Steinheim, GER 
Q5 Hot Start DNA polymerase New England Biolabs, Ipswich, USA 
Restriction endonucleases New England Biolabs, Ipswich, USA 
T4 DNA Ligase New England Biolabs, Ipswich, USA 
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DNeasy Blood and tissue kit Quiagen GmbH, Hilden, GER 
GenElute DNA miniprep kit Sigma-Aldrich, Steinheim, GER 
Guide-it™ Long ssDNA Production System Takara Bio, Göteborg, SWE 
MEGAclear kit Ambion, Austin, TEX, USA 
Mix2Seq kit Eurofins, Ebersberg, GER 
mMESSAGE mMACHINE T7 kit Ambion, Austin, TEX, USA 
NucleoBond Xtra Midi kit Macherey-Nagel, Düren, GER 
PlateSeq DNA kit Eurofins, Ebersberg, GER 
Poly-A tailing kit Ambion, Austin, TEX, USA 
PureYield™ Plasmid Miniprep kit Promega, Mannheim, GER 
SurePrep RNA/DNA/protein purification kit Fisher Scientific, Hampton, NH, USA 




E. coli ElectroMAX DH10B  Thermo Fisher Scientific, Waltham, MA, 
USA 
Porcine foetal fibroblasts 
(Isolate 170220) 
Chair of Livestock Biotechnology, TUM, 
Freising, GER 
Porcine kidney fibroblasts 
(Isolate 250515) 
Chair of Livestock Biotechnology, TUM, 
Freising, GER 
Porcine oocytes Schlachthof Ingolstadt GmbH, 
Ingolstadt, GER 






FUT1 F1 5‘ CCTCCGATTCCTGTCCCAAG 3‘ 
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FUT1 F2 5‘ TTAGACCTGCTGGCCCTGTG 3‘ 
FUT1 R1 5‘ CGGACATCCAGTCGTGAAGC 3‘ 
FUT1 R2 5‘ CGGAGGTGGTGGAAGAAGGT 3‘ 
FUT1 Scr F1 5‘ CGGGCTGCACTTATGACTGG 3‘ 
FUT1 Scr R1 5‘ TTGGGCATCACACGCAGATA 3‘ 
FUT1 tar amp F1 5‘ CCGCCACCTCTGTCTGACCT 3‘ 
FUT1 tar amp R1 5‘ GTGGTCGTGCAGGGTGAACT 3‘ 
Gal Scr E8 T4 F1 5‘ TCCCAGAGGTTACATTTACCCCA 3‘ 
Gal Scr E8 T4 R1 5‘ GCACATCCTGGCCCACATCC 3‘ 
GAPDH S. scrofa F 5‘ TTCCACGGCACAGTCAAGGC 3‘ 
GAPDH S. scrofa R 5‘ GCAGGTCAGGTCCACAAC 3‘ 
PX330 FUT 1 G20 R1 5‘ AAACGCAGCGTGGCATACTGTC 3‘ 
PX330 FUT1 G13 F1 5‘ CACCGCTGCCATGCACGCCGTCC 3‘ 
PX330 FUT1 G13 R1 5‘ AAACGGACGGCGTGCATGGCAGC 3‘ 
PX330 FUT1 G2 F1 5‘ CACCGACTATTTACCCGGATGGC 3‘ 
PX330 FUT1 G2 R1 5‘ AAACGCCATCCGGGTAAATAGTC 3‘ 
PX330 FUT1 G20 F1 5‘ CACCGACAGTATGCCACGCTGC 3‘ 
PX330 seq F1 5‘ GGGAGAAAGGCGGACAGGTA 3‘ 
PX330 seq R1 5‘ GCGGCATCAGAGCAGATTGT 3‘ 
PX330FUT1 G1 F1 5‘ CACCGTACCCGGATGGCCGGTTT 3‘ 
PX330FUT1 G1 R1 5‘ AAACAAACCGGCCATCCGGGTAC 3‘ 
 
 
4.1.7.2. gRNA oligonucleotides 
 
PX330 FUT1 G1 F1 5‘ CACCGTACCCGGATGGCCGGTTT 3‘ 
PX330 FUT1 G1 R1 5‘ AAACAAACCGGCCATCCGGGTAC 3‘ 
PX330 FUT1 G2 F1 5‘ CACCGACTATTTACCCGGATGGC 3‘ 
PX330 FUT1 G2 R1 5‘ AAACGCCATCCGGGTAAATAGTC 3‘ 
PX330 FUT1 G13 F1 5‘ CACCGCTGCCATGCACGCCGTCC 3‘ 
PX330 FUT1 G13 R1 5‘ AAACGGACGGCGTGCATGGCAGC 3‘ 
PX330 FUT1 G20 F1 5‘ CACCGACAGTATGCCACGCTGC 3‘ 
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PX330 FUT1 G20 R1 5‘ AAACGCAGCGTGGCATACTGTC 3‘ 
PX330 Gal-E8-T4-F 5‘CACCTAATAATACGACTCACTA 3‘ 




pX330-U6-Chimeric_BB-CBh-hSpCas9 Addgene, Cambridge, MA, USA  
pX330-U6-Chimeric_BB-CBh-hSpCas9- 
Gal-E8-T4 
Dr. Konrad Fischer, Chair of Livestock 
Biotechnology, TUM, Freising, GER 
 
4.1.9. DNA Ladders 
 
1 kb DNA ladder New England Biolabs, Frankfurt, GER 
100 bp DNA ladder New England Biolabs, Frankfurt, GER 
2-log DNA ladder  New England Biolabs, Frankfurt, GER 
 
4.1.10. Tissue culture media and supplements  
 
Accutase Sigma-Aldrich, Steinheim, GER  
Cell culture water Sigma-Aldrich, Steinheim, GER  
Collagenase Sigma-Aldrich, Steinheim, GER  
DMSO Sigma-Aldrich, Steinheim, GER  
Dulbecco’s Modified Eagle’s Medium Sigma-Aldrich, Steinheim, GER  
Foetal calf serum PAA Laboratories, Pasching, Austria 
G418 sulphate Genaxxon Bioscience, Ulm, GER 
GlutaMAX Gibco, BRL, Paisley, UK 
Hygromycin AppliChem, Darmstadt, GER 
Hypo-osmolar buffer Eppendorf, Hamburg, GER 
Lipofectamine 2000 Thermo Fisher Scientific, Waltham, MA, 
USA 
MEM non-essential amino acids 100x Sigma-Aldrich, Steinheim, GER  
Opti-MEM Gibco Life Technologies, Carlsbad, CA, 
USA 
Penicillin/Streptomycin Sigma-Aldrich, Steinheim, GER  
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Phosphate-buffered saline Sigma-Aldrich, Steinheim, GER  
Puromycin InvivoGen, San Diego, CA, USA 
Sodium pyruvate Sigma-Aldrich, Steinheim, GER  
Trypan blue Gibco Life Technologies, Paisley, GBR 
Trypsin-EDTA PAA Laboratories, Pasching, Austria 
 
4.1.11. Bacterial culture media and supplements 
 
Ampicillin Sigma-Aldrich, Steinheim, GER 
Chloramphenicol Sigma-Aldrich, Steinheim, GER  
LB medium (Luria-Bertani)  Becton Dickinson, Aalst, BEL  
 
4.1.12. Embryo culture media and supplements 
 
Amphotericin B Sigma-Aldrich, Steinheim, GER 
BSA Sigma-Aldrich, St. Louis, MO, USA 
Cysteine Sigma-Aldrich, St. Louis, MO, USA 
Epidermal growth factor (EGF) Sigma-Aldrich, St. Louis, MO, USA 
FBS Superior Biochrom GmbH, Berlin, GER 
Fibroblast growth factor (FGF) Sigma-Aldrich, St. Louis, MO, USA 
Hyaluronidase Sigma-Aldrich, St. Louis, MO, USA 
Insulin like growth factor (IGF) Sigma-Aldrich, St. Louis, MO, USA 
Suigonan (PMSG/ECG) MSD-Tiergesundheit, 
Unterschleißheim, GER 
Leukaemia inhibitory factor (LIF) Sigma-Aldrich, St. Louis, MO, USA 
Mineral oil Sigma-Aldrich, St. Louis, MO, USA 
Ovogest (HCG) MSD-Tiergesundheit, 
Unterschleißheim, GER 
Polyvinyl alcohol Sigma-Aldrich, St. Louis, MO, USA 
Porcine fertilisation medium (PFM) Fujihira Industry, Tokyo, JAP 
Porcine zygote medium 5 (PZM5) Fujihira Industry, Tokyo, JAP 
Sodium bicarbonate Sigma-Aldrich, St. Louis, MO, USA 
29 
4. MATERIALS AND METHODS  
 
Sodium pyruvate Sigma-Aldrich, St. Louis, MO, USA 
Tissue culture medium 199 Sigma-Aldrich, Steinheim, GER 
 
4.1.13. Solutions and buffers 
 
Type Components Quantity 




500 mg  
100 mg  
Add to 100 ml  
TAE 10x Tris 







Fill up to 5 l 





545 g  
275 g  
39.2 g  
Fill up to 5 l  
TE buffer Tris-HCl  
EDTA  
H2O  
158 mg  
29 mg  
Fill up to 100 ml  
 
4.1.14. Veterinary  equipment and products 
 
Ampitab® (Ampicillin)  Vetoquinol GmbH, Ismaning, GER 
Careflow Catheter 5F, 300mm Merit Medical, Jordan, UT, USA 
Cellulose swabs B. Braun AG, Melsungen, GER 
Electric cauter HBH Medizintechnik, Tuttlingen, GER 
Suigonan® MSD-Tiergesundheit, Unterschleißheim, 
GER 
Ketanest® (Ketamine) Elanco GmbH, Bad Homburg, GER 
Needle holder Omega Medical, Winnenden, GER 
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Razor B. Braun AG, Melsungen, GER 
Regumate® (Altrenogest) MSD-Tiergesundheit, Unterschleißheim, 
GER 
Scalpels Braun, Melsungen, GER 
Stresnil® (Azaperone) Elanco GmbH, Bad Homburg, GER 
Surgical drape B. Braun AG, Melsungen, GER 
Surgical gloves (Peha-taft) Omega Medical, Winnenden, GER 
Surgicryl 910 HS 48, 5 (2), 90cm  Omega Medical, Winnenden, GER 
Surgicryl DS 24, 3.0 (2/0) 75cm  Omega Medical, Winnenden, GER 
Syringes, (1ml,5ml,10ml,20ml) B. Braun AG, Melsungen, GER 




Benchling  https://www.benchling.com/ 
Chromatogram viewer” Finch TV” Digital world biology LLC, CA, USA 
Crispr design tool http://crispor.tefor.net/crispor.py 
Flow cytometry software “FlowJo” FlowJo LLC, Ashland, OR, USA  
Gel documentation software “Quantum ST5” Vilber Lourmat, Eberhandzell, GER 
Genome database “Ensembl”  https://www.ensembl.org/index.html 
Microscope software “Axio Vision” Carl Zeiss, Göttingen, Germany 
Sequence alignment tool “Clustal Omega”  https://www.ebi.ac.uk/Tools/msa/clust
alo/  
TIDE: Tracking of Indels by DEcomposition  https://tide.deskgen.com/ 









4.2.1. Molecular biology 
 
4.2.1.1. Isolation of genomic DNA 
 
Genomic DNA was extracted from eukaryotic cells using QuickExtract DNA extraction 
solution. Cells were detached with accutase, centrifuged at 300 x g for 5 minutes and 
resuspended in 30 μl QuickExtract DNA extraction solution. This solution was heated to 68 °C 
for 15 minutes followed by 98 °C for 8 minutes.  
If genomic DNA of higher purity was needed, the SurePrep DNA/RNA/Protein purification kit 
was used according to the manufacturer’s protocol. 
DNA from mammalian tissues or sperm was isolated by phenol-chloroform extraction. 
Approximately 1g of sperm pellet or tissue sample was incubated overnight in 1ml of lysis 
buffer at 55° C (see Table 1). The lysate was incubated with an equal amount of phenol-
chloroform-isoamyl alcohol (25:24:1) for 10 minutes at room temperature and centrifuged at 
13.000 x g for 10 minutes (same settings for all following centrifugation steps). The supernatant 
was mixed 1:1 with chloroform (99%) and centrifuged.  DNA precipitation was achieved by 
supplementation of 10% v/v sodium acetate (5M) and 0.7% v/v isopropanol followed by 
thorough shaking. The pellet was centrifuged, rinsed with 70% ethanol, and centrifuged again. 
The resulting DNA pellet was air-dried and dissolved in 20 μl sterile TE buffer. 
 
Table 1: Tissue lysis buffer 
Tris-HCL 83 mM 
SDS (sodium dodecyl sulphate) 0.8% 
EDTA 0.2 M 
NaCL 0.2 M 
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4.2.1.2. Isolation of plasmid DNA 
 
Depending on the required purity and quantity, different methods were used for the isolation of 
plasmid DNA from bacterial cultures.  
Plasmid bearing E. Coli bacteria were cultured overnight in LB-medium. If only small amounts 
of DNA were required a mini prep was performed using the PureYield™ Plasmid Miniprep kit 
according to the manufacturer’s instructions. 
Larger amounts of DNA for transfection, cloning or microinjection were extracted using the 
NucleoBond Xtra Midi Kit. The high-copy midi-prep protocol was carried out using 100ml of 
overnight culture according to the manufacturer’s instructions. 
 
4.2.1.3. Isolation of DNA from blastocysts 
 
DNA was isolated from blastocysts or single blastomeres to evaluate the efficiency of gene 
engineering. Blastocysts or blastomeres were rinsed twice with PBS and incubated in 10 µl of 
blastocyst DNA extraction buffer (see Table 2) for one hour at 65 °C, followed by ten minutes 
at 95°C. 
 
Table 2: Blastocyst DNA extraction buffer 
KCL 50 mM 
MgCl2 1.5 mM 
Nonidet P-40 0.5% (w/v) 
Proteinase K 100 µg/ml 
Tris-Cl (pH 8.0) 10 mM 
Tween-20 0.5% (v/v) 
 
 
4.2.1.4. Determination of DNA and RNA concentration 
 
The measurement of DNA and RNA concentrations was performed using the NanoDrop Lite 
spectrophotometer according to the manufacturer‘s protocol. 
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4.2.1.5. Polymerase chain reaction 
 
Polymerase chain reaction (PCR) was conducted to amplify specific DNA sequences from 
plasmid, genomic or cDNA templates. Different polymerases and protocols were chosen 
depending on the DNA template and length of the desired sequence. Amplification of short 
fragments from plasmid, genomic or cDNA templates was performed using GoTaq G2 
polymerase or FastGene Optima HotStart ready mix. Q5® high fidelity polymerase was used 
if proofreading was necessary or only low concentrations of DNA were available. The PCR 
extender system was used for long-range PCR. For thermal cycling conditions and PCR reaction 
compositions see Table 3-5. 
Table 3: GoTaq® G2 polymerase PCR reaction composition and thermal cycling conditions 
GoTaq® G2 polymerase 









DNA < 250 ng 
Initial 
Denaturation 
95°C 2 min 1 
5x buffer 1x Denaturation 95°C 30 sec 
35-40 
dNTPs 200 μm each Annealing 58-62°C 45 sec 
Primer F 0.2 μM Extension 72°C 1 min/kb 1 
Primer R 0.2 μM 
Final 
extension 
72°C 5 min 
 
Polymerase 0.03 U/μl Storage 8°C Indefinite 
H2O Add to 25 μl  
 
Table 4: PCR extender system reaction composition and thermal cycling conditions 
PCR extender system 
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DNA 100 ng 
Initial 
Denaturation 
93°C 3 min 1 
10x tuning buffer 1x Denaturation 93°C 30 sec 
10 dNTPs 500 μm each Annealing 60-64°C 1 min 
Primer F 0.4 μM Elongation 68°C 1 min/kb 




0.04 U/μl Annealing 60-64°C 1 min 
H2O Add to 50 μl Elongation 68°C 





68°C 5 min 1 
Storage 8°C Indefinite 1 
 
Table 5: Fastgene Optima HotStart PCR reaction composition and thermal cycling conditions 
FastGene Optima HotStart ready mix 









DNA 50 ng 
Initial 
Denaturation 
95°C 3 min 1 
FastGene Optima 
HotStart ready mix 
1x Denaturation 95°C 15 sec 
35-40 
Primer F 0.5 μM Annealing 58-62°C 15 sec 
Primer R 0.5 μM Elongation 72°C 1 min/kb 
H2O Add to 25 μl 
Final 
elongation 
72°C 5 min 1 
 Storage 8°C Indefinite  
 
Table 6: Q5® high-fidelity DNA polymerase PCR reaction composition and thermal cycling conditions 
Q5® high-fidelity DNA polymerase 
PCR reaction composition Thermal cycling conditions 
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98°C 30 sec 1 
Q5® 5x buffer 1x 
Denaturatio
n 
98°C 10 sec 
35-40 Q5® high GC 
enhancer (optional) 
1x Annealing 58-62°C 30 sec 
dNTPs 200 μm each Elongation 72°C 30 sec/kb 
Primer F 0.5 μM 
Final 
elongation 
72°C 2 min 1 
Primer R 0.5 μM Storage 8°C Indefinite 1 
Polymerase 0.02 U/μl 
 
H20 Add to 25 μl 
 
 
4.2.1.6. Agarose gel electrophoresis to separate DNA fragments 
 
Agarose gel electrophoresis was performed to analyse the size of DNA-fragments. Analytical 
gels were prepared with 1xTBE and preparative gels with 1xTAE buffer each supplemented 
with 4 μl PeqGREEN dye per 100 ml. The concentration of agarose was adjusted between 0.8-
2% according to the size of the expected DNA fragments. DNA fragments were mixed with 
loading dye, applied to the gel and 80-120V were applied until adequate separation was 
achieved (approximately 1 to 7 hours). The separated DNA fragments were visualised under 
UV light (254-366nm) using the Bio Imaging System Quantum ST5. 
 
4.2.1.7. DNA isolation from agarose gels 
 
DNA bands were visualised by UV light und cut out with a surgical blade. DNA purification 
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4.2.1.8. Proteinase K digest 
 
Proteinase K digest was conducted to inactivate nucleases and prevent the degradation of DNA 
during purification. The DNA was co-incubated with SDS (0.5%) and Proteinase K (1 μg/μl) 
for 30 minutes at 50°C. 
 
 
4.2.1.9. DNA purification 
 
Purification of DNA fragments and PCR products was conducted using the Wizard® SV Gel 
and PCR Clean-Up System or SurePrep DNA purification kit according to the manufacturer’s 
instructions. 
Prior to sequencing PCR products were enzymatically purified to remove residual primers and 
dNTPs. The PCR product was co-incubated with 0.2 μl exonuclease I and 0.4 μl antarctic 
phosphatase at 37°C for 30 min, followed by 15 minutes at 80°C.  
DNA templates for in vitro transcription were purified by modified phenol-chloroform 
extraction. DNA was mixed 1:1 with phenol-chloroform-isoamyl alcohol, vortexed and 
incubated in a phase lock gel for 10 minutes followed by centrifugation at 14.000 rpm for 10 
minutes. The DNA containing supernatant was incubated with two volumes of 100% ethanol 
and 1/10 volume 5M ammonium acetate at -20°C for 2 hours. The DNA was pelleted by 
centrifugation and the pellet was air dried and resuspended with 20 μl nuclease-free water. 
 
4.2.1.10. Sequencing of DNA fragments 
 
DNA sequencing was performed by Eurofins Genomics (Ebersberg, GER). Samples were 
prepared for sequencing following the manufacturer’s instructions using the Mix2Seq kit. 
 
4.2.1.11. Oligonucleotide annealing 
 
Complementary single-stranded oligonucleotides were diluted to a final concentration of 10ng/ 
μl with TE buffer. Double-strand hybridisation was achieved by heating the solution to 100°C 
for 5 min and then letting it cool to room temperature. 
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4.2.1.12. Restriction digestion 
 
Analytical restriction digests were performed to verify plasmid size. Preparative restriction 
digests were conducted to linearize targeting vectors for cloning. All restriction digests were 
conducted at the optimal temperature for each enzyme according to the manufacturer’s 
instructions. To prevent re-ligation the 5’ phosphates were removed from the vector backbone 
by incubation by alkaline phosphatase for 30 minutes at 37°C. The conditions for analytical and 
preparative restriction digestions are shown in Table 7. 
Table 7: Conditions for analytical and preparative restriction digestions 
Analytical digest Preparative digest 
Component Concentration Component Concentration 
DNA 0.2-3 μg DNA  7-40 μg 
10x NEB Buffer 1x 10x NEB Buffer 1x 
Enzyme 3-5 U/ μg Enzyme 5 U/ μg 
H2O add to 20-50 μl H2O add to 50 μl 
 
4.2.1.13. Blunting of DNA fragments 
 
DNA Polymerase I Large (Klenow) Fragment was used to remove 3’ overhangs and fill in 5’ 
overhangs of DNA fragments with incompatible sticks ends prior to ligation. The reaction was 
performed according to the manufacturer’s instructions. DNTPs (60 μM) were added to inhibit 
the 3’-5’ exonuclease activity of the polymerase. All reagents were incubated at 25 °C for 15 
minutes. The reaction was stopped by adding 10 mM EDTA and increasing the temperature to 
75 °C for 20 minutes. Table 8 shows the conditions for blunting reactions. 
Table 8: Conditions for blunting reactions  
Component Final concentration 
DNA 5 μg  
10x NEBuffer 1x 
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dNTPs (2mM) 50 μM 
Enzyme 1U/ μg  
H2O add to 50 μl 
 
4.2.1.14. Ligation of oligonucleotides into vector backbones 
 
Vector backbones and insert DNA fragments were ligated using T4 Ligase. Ligation reactions 
were set up according to the manufacturer’s instructions and incubated for two hours at room 
temperature, followed by 4°C overnight. Ligation reaction conditions are shown in Table 9. 
Table 9: Conditions for ligation reactions 
Component Final concentration 
Hybridised oligonucleotides 1.5 μL 
10x T4 Ligase buffer 1x 
T4 DNA Ligase 1.5 μL 
Digested vector backbone 100 ng 
H2O add to 15 μl 
 
4.2.1.15. Colony PCR 
 
Colony PCR was performed to identify E. Coli colonies carrying the intended plasmid 
constructs. One primer was designed to bind to the plasmid insert, the other to the plasmid 
backbone. Single bacterial colonies were resuspended in 30 μl TTE buffer and incubated at 
95°C for 5 minutes to generate template DNA for the GoTaq PCR reaction (see Table 3).  
 
4.2.1.16. In vitro transcription  
 
SgRNAs were generated by in vitro transcription of DNA templates using the MEGAshortscript 
T7 kit as instructed by the manufacturer. In vitro transcription of DNA templates encoding 
RNA transcripts of 0.3-5kb was performed using the mMESSAGE mMACHINE T7 kit 
according to the manufacturer’s instructions. Purification and polyadenylation of the RNA 
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transcript was carried out using the Poly-A tailing kit and MEGAclear kit according to the 
manufacturer’s protocol. 
 
4.2.1.17. Generation of CRISPR/Cas9 components 
 
CRISPR gRNAs with low predicted off-target effects were identified using an online CRISPR design 
tool (https://www.benchling.com/). Oligonucleotides containing a single G for U6 promoter 
transcription followed by the target guide sequence and overhangs compatible to the BbsI-
digested vector backbone were purchased from MWG Eurofins Genomics (Ebersberg, GER). 
The single-stranded oligonucleotides were hybridised and ligated into the pX330-U6-
Chimeric_BB-CBh-hSpCas9 vector (see Figure 6). Bacterial cells were transformed , positive 
clones were confirmed by sequencing and plasmid DNA was extracted using the NucleoBond 
Xtra Midi kit and directly used for microinjection or DNA transfection. 
For in vitro transcription the gRNA encoding sequence was amplified by Q5® high-fidelity 
polymerase followed by gel-purification and a 4-fold nested PCR. The PCR product was 
enzymatically purified, digested with proteinase K and purified by phenol-chloroform 
extraction. In vitro transcription was performed using the MEGAshortscript T7 kit followed by 
purification using the MEGAclear kit according to the manufacturer’s instructions.  
 
 
Figure 6: Generation of pX330-U6-Chimeric_BB-CBh-hSpCas9. The annealed oligonucleotides were cloned into 
the digested vector backbone. The vector contains the U6 promoter, sgRNA scaffold, CBh promoter, nuclear 
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4.2.1.18. Tracking of Indels by Decomposition 
 
Sequences from cell pools were analysed using the TIDE (Tracking of Indels by 
Decomposition) online tool. To facilitate the identification and quantification of insertions and 
deletions (indels) PCR amplification was performed across the target site followed by DNA 
sequencing of the PCR product. The frequency of mono- and biallelic mutations was 
determined by calculating the total proportion of edited cells. TIDE determines the spectrum 
and frequency of mutations at a specific sequence withing a cell pool from sequencing data. 
Only data with a statistical R2 value above 0.9 which indicates low negative interference by 
sequencing noise or large deletions was considered in the analysis. 
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4.2.2.1. Bacterial cell cultivation 
 
Bacterial cells were grown on agar plates supplemented with antibiotics or in LB medium on 
an orbital shaker. Single bacterial clones were picked from an agar plate and cultivated 
overnight at 37°C in LB medium supplemented with 100 μg/ml ampicillin or on agar plates. 
For blue-white screening plates were coated with X-Gal and Isopropyl-β-D-
thiogalactopyranoside (IPTG). 
 
4.2.2.2. Bacterial cell preservation 
 
Bacteria carrying plasmids of interest were prepared for long-term storage by mixing 1ml of 
overnight culture 1:1 with glycerol (99%). Glycerol stocks were stored at -80°C. 
 
4.2.2.3. Bacterial cell transformation 
 
Electrocompetent bacteria were transformed by electroporation to introduce plasmids. Plasmids 
(10-30 pg) were co-incubated with 50 μL of ElectroMAX DH10B E. coli bacteria in an 
electroporation cuvette (electrode distance 2mm). Cells were electroporated at 2.5kV, 5ms and 
incubated in LB medium without antibiotics for 30 minutes at 37°C. Subsequently the 
transformed bacteria were plated on LB agar supplemented with antibiotics and cultivated 
overnight at 37°C.  
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4.2.3.1. Oocyte isolation 
 
Ovaries were sourced from a local slaughterhouse and transported at 38°C in PBS supplemented 
with Amphotericin B and Penicillin/Streptomycin (Pen/Strep) (1% each). They were rinsed 
twice with warm PBS solution and maintained at 38°C during the whole isolation process. A 
10ml syringe and 18G needle was used to puncture follicles (Ø 3-6mm). Cumulus-oocyte-
complexes with dark, evenly granulated cytoplasm covered by multiple compact layers of 
cumulus cells were selected under a stereomicroscope. To remove cell detritus the oocytes were 
rinsed twice in working medium (tissue culture medium 199 supplemented with 10% (FCS, 1% 
Pen/Strep and 1% Amphotericin B). 
 
4.2.3.2. Oocyte maturation 
 
Groups of 50 oocytes were transferred to four-well plates containing 500 µl of maturation 
medium (see Table 10) and placed in a triple gas incubator at 38,5°C humidified atmosphere 
for 45 hours. Successful maturation was confirmed by extrusion of the first polar body.  
 
Table 10: Maturation medium 
Cysteine 0.57mM 
Epidermal growth factor 10ng/ml 
Fibroblast growth factor II 40ng/ml 
Glucose 3.05mM 
HCG/ECG 1 IU/ml each 
Insulin-like growth factor I 20ng/ml 
Leukaemia inhibitory factor 20ng/ml 
Polyvinyl alcohol 0.1% w/v 
Sodium pyruvate 0.91mM 
Tissue culture medium 199 add to desired volume 
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4.2.3.3. Parthenogenetic activation 
 
Parthenogenesis was conducted to provide a control group for IVF experiments and to analyse 
the efficiency of gene editing after microinjection.  
After in vitro maturation (45 hours) the cumulus cells were enzymatically removed (1mg/ml 
hyaluronidase). Zygotes showing extrusion of the first polar body were rinsed with activation 
medium (see Table 11), transferred to an activation chamber (ø 1mm) and activated with a 
single DC pulse (150V, 100µs). After parthenogenesis the oocytes were cultivated in PZM5 
supplemented with 5µg/ml Cytochalasin B and 10µg/ml Cycloheximide for 4 hours. Afterwards 
they were rinsed in PZM5 and cultivated in PZM5 (6 days) to the blastocyst stage. 
Table 11: Activation medium 
CaCl2 0.05 mM 
H2O Add to desired volume 
Mannitol 280 mM 
MgSO4 0.1 mM 
PVA 0.01 % w/v 
Sterile filtrate (22µm), adjust PH to 7.2-7.4, adjust osmolarity to 300 Ω. 
 
4.2.3.4. In vitro fertilisation 
 
Groups of 50 oocytes were placed in 500 µl of equilibrated porcine fertilisation medium (PFM). 
Frozen sperm was thawed, then rinsed with sperm diluent (Androstar® Plus) and centrifuged 
(800G, 3 min) to remove cryo-protectants. The pellet was mixed with 500 µl of PFM and 
analysed concerning motility, morphology, and sperm concentration. In vitro fertilisation (IVF) 









Cumulus cells were enzymatically removed (1mg/ml hyaluronidase) and zygotes showing 
extrusion of the second polar body were selected for microinjection. Groups of 50 zygotes were 
placed in a 10 µl droplet of working medium covered by mineral oil. The gene editing vectors 
were diluted to a final concentration of 5 ng/µl with low-tris EDTA buffer (10 mmol/L Tris-
HCL, pH 7.6 and 0.25 mmol/L EDTA, pH 8.0) and backfilled into microinjection needles. 
The injection needle was gently opened by tapping it with the holding needle. Zygotes were 
fixated with the polar body located at the twelve or six o’ clock position, the injection needle 
was gently inserted into the ooplasm and about  10 pl of solution were dispensed. 
For two-cell stage injection zygotes were cultivated for 24 hours after IVF and embryos that 
had undergone the first cleavage division were selected for microinjection. Microinjection was 
performed as described above but the injection solution was only delivered into one out of two 
blastomeres. Injection pressure was reduced to accommodate the smaller size of the 2-cell-stage 
blastomere and approximately 5pl of injection solution were dispensed. 
 
4.2.3.6. Embryo cultivation 
 
Groups of 50 zygotes were rinsed with porcine zygote medium 5 (PZM5) and cultivated in the 
triple gas incubator in 500 µl of PZM covered by mineral oil. Zygotes destined for DNA 
extraction and analysis were cultured in vitro for six days until they reached the blastocyst stage. 
Zygotes designated for embryo transfer were cultivated for 12-36 hours in vitro and their 
viability was visually assessed prior to embryo transfer. 
 
4.2.3.7. Production of microinjection needles 
 
Microinjection needles were manufactured with a P-97 Flaming brown micropipette puller 
according to the manufacturer’s protocol (see Table 12). Optimal melting temperatures for 
borosilicate glass tubing were determined by conducting a temperature ramp test. Holding 
pipettes (Vacutip I®, Eppendorf, Hamburg, GER) were purchased. 
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4.2.3.8. Embryo transfer 
 
Synchronisation of gilts (aged 6 months, weight 120kg) was conducted by oral administration 
of Altrenogest (Regumate®) for 15 days followed by two intramuscular injections of 750 IU 
HCG/ECG (Suigonan®) one and five days later. Embryo transfer was conducted one to two 
days after the last injection.  
Fasted pigs were anaesthetised by intravenous application of 20 mg/kg ketamine (Ketanest®) 
and 2mg/kg xylazine (XYLAPAN®) and given 15mg/kg ampicillin (Ampitab®) and 0.4mg/kg 
meloxicam (Metacam®). Recipients were fixated on the surgery table, the abdomen was 
cleaned with warm water and disinfected with iodine solution. The surgery area was covered 
with a surgical drape and the skin excision was made at the Linea Alba between the last two 
pairs of teats. The abdomen was opened, one ovary was displaced, and the correct state of the 
reproductive cycle was visually confirmed by the presence of fresh ovulation sites. 
Approximately 150 to 200 embryos were gently dispensed into the recipient’s oviduct with a 
sterile catheter (Careflow®). The surgical wound was stitched in three layers using Sultan's 
diagonal suture for peritoneum and muscle and the mattress suture technique for skin.  
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4.2.4. Cell culture 
 
4.2.4.1. Cell isolation 
 
Wild type porcine kidney fibroblasts (PKFs) were isolated from kidneys obtained from the 
TUM animal facility Thalhausen or from a local slaughterhouse. Approximately 1g or kidney 
tissue was rinsed twice with 80% ethanol and PBS solution. The tissue was chopped into small 
pieces and enzymatically dissociated by incubation in 10ml collagenase A (10mg/ml) at 37°C 
for 30 minutes on a magnetic stirrer. The cells were centrifuged for 5 minutes at 300 x g and 
the cell pellet was resuspended in warm cell culture medium supplemented with amphotericin 
B and pen/strep. After seven days cells were cultivated under antibiotic-free conditions. All 
steps were carried out in a laminar flow using sterile equipment. 
For the isolation of porcine foetal fibroblasts (PFFs), the pregnancy was sonographically 
confirmed on and the surrogate pig was humanely killed. The foetuses were extracted from the 
uterus and approximately 1g of foetal tissue was used for cell isolation. All further steps were 
carried out a described above. 
 
4.2.4.2. Cell cultivation 
 
PKF and PFF cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 2mM Ala-Gln, 1mM sodium pyruvate, 1x MEM non-essential amino acid 
solution (NEAA) and 10% FCS at 5% CO2, 37°C in humified atmosphere. Medium was 
exchanged every three days. Cells were passaged when reaching 90% confluence by detaching 
them with accutase and transferring them to a new tissue culture vessel. 
 
4.2.4.3. Cell counting 
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4.2.4.4. Cell transfection 
 
Cells were transfected with DNA by electroporation or lipofection. 
Prior to electroporation cells were detached from the cell culture flask with accutase, 1x106 
cells were counted and centrifuged for 5 minutes at 300 x g. The cell pellet was resuspended in 
400μl hypoosmolar buffer and gently mixed with 5-6 μg linearized vector DNA. The mixture 
was incubated at room temperature for 5 to 10 minutes in an electroporation cuvette (electrode 
gap 4mm). Electroporation was conducted by applying a 1200 V pulse for 85μs and the cell 
suspension was divided into three cell culture vessels with fresh medium. 
 
For lipofection cells were seeded at 50% confluency, rinsed with PBS, and cultured in Opti-
MEM medium in 10cm cell culture plates. A transfection and DNA solutions were prepared by 
diluting 6μl Lipofectamine 2000® and 5 μg DNA with OptiMEM to a final volume of 300 μl 
respectively. Both solutions were incubated at room temperature for 5 minutes, gently 
combined, and co-incubated for another 20 to 25 minutes. The solution was gently applied onto 
the cells and cultivated. After 5 hours DMEM medium was added, the cells were cultured 
overnight, and a medium change was conducted on the next day. 
 
4.2.4.5. Antibiotic selection 
 
Cell clones were selected for stable transgene integration using cell culture medium 
supplemented with the corresponding antibiotic for the plasmid’s resistance cassette. The 
appropriate concentration of antibiotics for each cell type was determined in a killing curve 
experiment. Selection medium was performed until single cell clones without background 
became apparent. In this project selection was conducted using G418 (Geneticin) and 
puromycin. 
 
4.2.4.6. Isolation of single cell clones 
 
Separated cell colonies were marked and cloning rings were fixated over each colony with 
silicon grease. Accutase was dispensed into each cloning ring to detach the cells. The cell 
suspension was transferred into 6-well cell plates and cultivated. 
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4.2.4.7. Cell cryopreservation and thawing 
 
Cells were detached with accutase and centrifuged at 300 x g for 5 minutes. The cell pellet was 
resuspended in 1.5ml of cryopreservation medium (70% FCS, 20% DMEM and 10% dimethyl 
sulfoxide). This suspension was transferred into cryo-vials, and frozen at -80 °C in Mr. Frosty® 
cell freezing containers. For long-term storage cells were conserved in the gas phase of liquid 
nitrogen containers.  
Thawing of cells was conducted by transferring the cryo-vials to a water bath (37°C) until the 
medium was nearly thawed. The cells were pelleted by centrifugation (300 x g, 5 minutes), 
resuspended in prewarmed DMEM medium and cultivated (5%CO2, 37°C). 
 
4.2.4.8. Magnetic-activated cell sorting 
 
Magnetic-activated cell sorting (MACS) was performed to separate galactose-α-1,3-galactose 
(α-Gal) negative and positive cells. PFF cells were isolated as described in 4.2.4.1., rinsed with 
PBS and centrifuged (300 x g, 5 minutes). The cell pellet was resuspended with 50μl isolectin 
B4 (0.5 mg/ml, biotin conjugated) and incubated on ice for 15 minutes. The cells were rinsed 
with PBS, centrifuged (300 x g, 5 minutes) and co-incubated with 200 μl purified, streptavidin 
coated magnetic beads (Dynabeads®, biotin binding) on ice for 30 minutes. A magnetic field 
was applied for 1 minute, and the supernatant containing the αGal-negative cells was collected 
whereas the αGal-positive cells remained bound to the magnetic beads. The purity of sorted 
cells was analysed by flow cytometry. Figure 7 schematically depicts the process for the 
separation of α-Gal positive and α-Gal negative cells. 
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Figure 7: Separation of α-Gal positive and negative cells by magnetic-activated cell sorting. Streptavidin coated 
magnetic beads bind to the biotinylated isolectin B4. A magnetic field is applied, and the α-Gal negative cells are 
removed whereas the α-Gal positive cells remain bound to the magnetic beads.  
 
4.2.4.9. Flow cytometry 
 
For flow cytometry 1x106 PFF cells were transferred to each well of a 96-well plate, washed 
and resuspended in fluo buffer (PBS supplemented with 0.1mg/ml sodium-azide and 1% BSA). 
Cells were incubated with Isolectin B4, biotin conjugated for 20 minutes on ice. Then they were 
washed with fluo buffer and incubated with PE-streptavidin for 20 minutes on ice. Finally, cells 
were washed and resuspended in 300 μl of fluo buffer and flow cytometry measurements were 















The goal of this thesis was to evaluate the feasibility, efficiency, and safety of gene editing in 
pigs by the example of Oedema disease. 
For this purpose, guide RNAs with low predicted off-target activity were identified, Cas9 
vectors were generated, primary porcine cells were transfected, and the most efficient gRNAs 
were determined by TIDE analysis. Primary porcine cell isolates were screened for their FUT1 
genotype and gene editing was performed using single stranded oligonucleotides and 
CRISPR/Cas expression vectors. Single cell clones were selected, expanded and the efficiency 
of gene editing was analysed (described in 5.1.). 
Precise in vivo editing of the FUT1 gene was attempted directly in porcine embryos. Cas9 
vectors and single stranded DNA repair templates were delivered to in vitro fertilised porcine 
zygotes by microinjection. Genetically modified embryos were generated, and the editing 
efficiency was analysed by PCR and DNA sequencing (addressed in 5.2.). 
 
In the second part of this project the frequency at which the CRISPR/Cas9 system generates 
off-target mutations in vivo was analysed using a novel approach termed GOTI never before 
applied in livestock. This approach facilitates a differentiation between natural mutations that 
occur during embryogenesis and off-target mutations.  
Cas9 expression vectors were microinjected into one blastomere of a two-cell stage embryo to 
generate mosaic foetuses containing both edited and non-edited cells simultaneously. An 
essential prerequisite is the ability to separate edited and non-edited cells from a single foetus. 
Therefore, the GGTA1 gene was chosen as the target for genome engineering. Its inactivation 
leads to the absence of the α-Gal surface epitope which allows the precise separation of edited 
and non-edited cells. The microinjected embryos were transferred to surrogate sows, one 
pregnancy was established and terminated on day 38. Fourteen foetuses were isolated, three of 
them mosaic and foetal fibroblasts were isolated.  Edited and non-edited cells were separated 
via magnetic-activated cell sorting. Whole genome sequencing was performed to analyse the 
frequency of off-target mutations caused by CRISPR/Cas9 mediated in vivo gene editing in 
livestock, irrespective of naturally occurring mutations (outlined in 5.3.).   
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5.1. In vitro editing of the FUT1 gene 
 
Genetics play a decisive role in animal health. Gene editing technology could complement 
traditional breeding techniques to improve animal welfare. This project aimed to establish 
methods for precise, efficient, and safe gene editing in pigs to improve animal welfare by the 
example of Oedema disease.  
Animals carrying a specific variant of the FUT1 gene (Chr.6:49826013A>G) which mediates 
an amino acid exchange (p.T103A) are resistant to Oedema disease. Gene editing was used to 
precisely elicit this single A>G base pair exchange and thereby convert FUT1-GG into FUT1-
AA cells.  
 
5.1.1. Identification of FUT1 gRNA sequences 
 
Four different gRNAs for the FUT1 gene (FUT1 G1, G2, G3, G20) with high predicted on-
target and minimal predicted off-target activity were identified using an online CRISPR design 
tool (http://crispor.tefor.net/crispor.py). Each gRNA was cloned into a Cas9 expression vector 
containing a puromycin resistance cassette to facilitate transient selection in primary porcine 
cells.  
Porcine kidney fibroblasts (PKFs) from eight donor animals were screened for their FUT1-GG, 
-GA, or -AA genotype by PCR and DNA sequencing. Seven cell isolates had the FUT1-GG 
genotype, one cell isolate the FUT1-AG genotype. Only cell isolates with the FUT1-GG 
genotype were used to facilitate a precise determination of gene editing efficiencies.  
PKFs were transfected with each expression vector and selected with puromycin. DNA was 
isolated from each transfected cell pool and PCR amplification was conducted across the target 
site followed by DNA sequencing. The frequency of insertions and deletions at the target site 
was determined by TIDE analysis (see Figure 8).  
The most efficient gRNA (FUT1 G20) caused the highest frequency of indel mutations at the 
target site (37,1%) and was therefore used for all further experiments. 
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Figure 8: The spectrum and frequency of insertions and deletion at the FUT1 target site determined by TIDE 
analysis. A) FUT1 G1 (30,8%), B) FUT1 G2 (33,2%), C) FUT1 G3 (30,4%), D) FUT1 G20 (37,1%) 
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5.1.2. Evaluation of FUT1 repair templates 
 
Single-stranded DNA repair templates with different lengths (700-3000 bps) were synthesized 
using the Guide-it™ Long ssDNA Production System according to the manufacturer’s protocol. 
The repair templates were individually co-transfected with the most efficient Cas9 expression 
vector (G20) into porcine somatic cells. DNA was extracted from the cell pool and analysed by 
DNA sequencing. The single-stranded DNA repair template ssOliFUT1 (700bp) led to the 
highest repair efficiencies (>90%) in the cell pool and was therefore used for all further 
experiments (see Figure 9). 
 
 
Figure 9: A) Sequencing of the FUT1 gene in the original cell population (FUT1-GG genotype, highlighted in 
blue), B) Sequencing of the FUT1 gene after transfection with the CRISPR/Cas9 FUT1G20 expression vector and 
ssOliFUT1 ssDNA repair template (cell pool DNA). Sequencing data reveal a distinct signal for adenosine (FUT1-
AA genotype, highlighted in blue). A double peak would be observed here if there was still a quantifiable 
proportion of cells with the FUT1-GG or GA genotype in the cell pool). 
 
Single cell clones with the FUT1-AA genotype were isolated and could be used as nuclear 
donor cells for somatic cell nuclear transfer. However, the generation of genetically modified 
animals was not planned within this project. 
 
In summary, the goal of precisely and efficiently correcting a gene variant with adverse effects 
on animal health (FUT1-GA or FUT1-GG) by gene editing could be met. Cas9 expression 
vectors and DNA repair templates were designed and tested in vitro. In porcine somatic cells 
the desired G>A base exchange could be conducted with an efficiency of more than 90% which 
was confirmed by DNA sequencing. 
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5.2. In vivo editing of the FUT1 gene 
 
The Cas9 expression vector and single stranded DNA repair template that had been identified 
and tested in vitro were used to perform in vivo gene editing in porcine embryos.  
 
5.2.1. Preliminary experiments in parthenotes 
 
The efficiency of gene editing and embryotoxicity was assessed using parthenogenetically 
activated embryos. Ovaries were sourced from a local slaughterhouse, oocytes were extracted 
and matured in vitro. The GE vector (5ng/µl) and DNA repair template (10ng/µl) were 
microinjected into the cytoplasm of 100 in vitro matured oocytes followed by parthenogenesis 
and in vitro cultivation. 100 non-injected embryos were parthenogenetically activated and 
cultivated as a control group. In the microinjected group 29/100 embryos developed to the 
blastocyst stage compared to 42/100 in the control group. The efficiency of gene editing was 
analysed by isolating DNA from each blastocyst followed by PCR amplification across the 
target site and DNA sequencing. 
In the microinjected group the FUT1-AA genotype was detected in 27/29 embryos (93%). 
However, in the non-injected control group the FUT1-AA genotype could also be detected in 
28/42 embryos (66.6%). This shows that within the local pig population a higher proportion of 
animal than previously anticipated based on the literature already had the resistant FUT-1 AA 
genotype.  
The evaluation of sequencing data from 12569 pigs revealed allele frequencies for the FUT1-
AA, -AG and -GG genotypes of Piétrain (PI) (7%/41%/52%), Deutsches Edelschwein (DE) 
(44%/41%/15%) and German Landrace (DL) (0%/11%/89%). The incidence of the FUT1-AA 
genotype was higher than previously known, particularly in PI (7%) and DE (44%) 
(unpublished data, Prof. Fries, Chair of Animal Breeding, TUM).  
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5.2.2. Editing of the FUT1 gene in IVF zygotes 
 
5.2.2.1. Identification of FUT1-GG sperm isolates for IVF 
 
The FUT1 genotype of in vitro matured oocytes is unknown because they are sourced from a 
diverse group of donor animals at the slaughterhouse. Therefore, FUT1 GG sperm is required 
for IVF to prevent the generation of FUT-1 AA embryos by breeding. In total, 15 samples of 
frozen sperm were obtained from Bayern Genetik. DNA was isolated by phenol-chloroform 
extraction followed by PCR amplification across the target site and DNA sequencing (see Table 
13). 
 
Table 13: FUT1-Genotype of 15 sperm isolates. 
Name Breed FUT1-genotype 
Cadura Piétrain GG 
Fadros Piétrain AG 
Fadros Piétrain AG 
Iberico Piétrain GG 
Madura Piétrain AG 
Mozzi Piétrain GG 
Orloki Large White AG 
Pablura Piétrain GG 
Ryder Large White AA 
Wadtbandt Piétrain AG 
Wadthose Piétrain AA 
Wadtlist Piétrain AG 
Wadtpill Piétrain GG 
Wadttext Piétrain AG 
 
Out of 15 sperm isolates, two were FUT1-AA, eight FUT1-AG and six FUT1-GG. Sperm from 
all six FUT1-GG boars was examined for its IVF suitability. The best results (16% blastocyst 
development) were obtained using sperm from the boar Cadura which was therefore used for 
all further experiments. 
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5.2.2.2. Gene editing in IVF zygotes 
 
IVF was conducted (as described in 4.2.3.4.) using FUT1-GG sperm followed by microinjection 
of the Cas9 expression vector and single-stranded DNA repair template that had been 
previously tested in cell culture and parthenotes. 100 microinjected embryos and a control group 
of 100 non-injected embryos were cultivated for 6 days. In the microinjected group 16/100 
embryos and in the control group 20/100 embryos developed to the blastocyst stage (see Figure 
10).  
 
Figure 10: A) Blastocyst development after IVF and microinjection with the gene editing vector and ssDNA repair 
template. B) Non-injected control group 
 
The FUT1 genotype of the blastocysts was determined by performing DNA isolation followed 
by PCR amplification across the target site and DNA sequencing. In the injected group 15/16 
blastocysts (94%) had the FUT1-AA and one blastocyst (6%) the FUT1-AG genotype (see 
Figure 13). In the non-injected control group, six blastocysts (30%) had the FUT1-AG and 14 
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Figure 11: A) Sequencing of the FUT1 gene in a blastocyst from the non-injected control group (FUT1-GG 
genotype). B) Sequencing of the FUT1 gene in a blastocyst after microinjection with the GE vector plus repair 
template (FUT1-AA genotype). 
 
In summary, efficient in vivo gene editing was successfully conducted in porcine zygotes. 
However, preliminary work in parthenotes revealed that the frequency of the FUT1-AA 
genotype within the local pig population was higher than anticipated based on the literature. 
These findings were later confirmed by new sequencing data provided by the Chair of Animal 
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5.3. Off-target analysis by two-cell-stage microinjection 
 
Off-target mutations are usually analysed by screening of in silico predicted off-target sites or 
by WGS [87]. The fundamental problem with this these approaches is the differentiation 
between off-target mutations caused by the CRISPR/Cas9 system and natural mutations that 
occur during embryonic development (~60-80 in each individuum) [12].  
Here, mosaic foetuses containing both edited and non-edited cells were generated by two-cell-
stage microinjection. Both cell types were separated and analysed by whole genome sequencing 
(WGS) to facilitate the comprehensive analysis of off-target mutations. The comparison 
between edited and non-edited cells from the same individual promises a precise differentiation 
between off-target mutations and natural mutations. Figure 12 schematically depicts the 
experimental setup. 
 
Figure 12: Genome-wide „off-target“ analysis by microinjection into two-cell stage embryos. Mosaic foetuses 
were generated by two-cell stage microinjection followed by embryo transfer. The pregnancy was aborted, foetuses 
were extracted and edited, and non-edited cells were separated. The Frequency of on-target, off-target and natural 
mutations was analysed. 
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5.3.1. Generation of mosaic foetuses by two-cell stage microinjection 
 
The GGTA1 gene which codes for the enzyme α-1,3 galactosyltransferase was chosen as the 
target for gene editing. Inactivation of the GGTA1 gene leads to a loss of the α-1,3-galactosyl 
(α-Gal) cell surface epitope. This allows the precise separation of the α-Gal positive (non-
edited) and α-Gal negative (edited) cell populations. The required Cas9 expression vectors had 
been previously tested and successfully used to generate α-Gal negative pigs (provided by Dr. 
Konrad Fischer, Chair of Livestock Biotechnology, TUM) [130]. 
 
Ovaries were collected at a local abattoir, oocytes were extracted, in vitro matured, and in vitro 
fertilised. The zygotes were cultivated for 24 hours until they had reached the two-cell stage. 
The CRISPR/Cas9 expression vector was delivered into only one of two blastomeres by 
intracytoplasmic microinjection (see Figure 13). 
 
Figure 13: Two-cell stage microinjection. To generate mosaic foetuses the CRISPR/Cas9 expression vector was 
delivered to one blastomere of a two-cell stage embryo.  
 
Two embryo transfers were conducted in which 160 - 180 microinjected embryos were 
transferred to hormonally synchronised recipients. One pregnancy was sonographically 
confirmed on day 28. The sow was euthanised on day 38 and 14 foetuses were extracted (see 
Figure 14).  
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Figure 14: Fourteen foetuses resulting from two-cell stage microinjection.  
 
Porcine foetal fibroblasts were isolated from each foetus. DNA was extracted from each 
individual cell population, followed by PCR amplification across the target site and DNA 
sequencing to ascertain the genotype of the embryos.  
Eight foetuses were wild type and the GGTA1 gene was modified in 6/14 foetuses (42%). Three 
of the gene edited foetuses had a homozygous inactivation of the GGTA1 gene and three 
foetuses were mosaic as desired. 
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5.3.2. Separation of edited and non-edited cell populations 
 
Edited and non-edited cell populations from each individual mosaic embryo were separated by 
magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS). 
 
5.3.2.1. Fluorescence-activated cell sorting 
 
FACS was performed to separate the different cell populations within each mosaic embryo 
(carried out by Kristiyan Kanev, Chair of Animal Physiology and Immunology, TUM). An 
efficient separation of α-Gal positive and negative cells could be achieved but FACS reduced 
cell viability (see Figure 15). 
 
Figure 15: Separation of α-Gal positive and negative cells via FACS. From left to right: Gating of cell populations. 
P1/P1: mixed cell population; P3: α-Gal negative (GGTA1 knockout) cells; P4: α-Gal positive (wild type) cells 
 
5.3.2.2. Magnetic-activated cell sorting 
 
MACS was established as a method for the separation of α-Gal positive and negative cell 
populations because the viability of cells after separation was higher with this method compared 
to FACS. Cells with intact α-Gal glycosylation were marked with biotinylated Isolectin B4 that 
binds to streptavidin coated magnetic beads. Separation of cell populations was conducted 
under a magnetic field. The efficiency of separation was analysed by TIDE analysis (see Figure 
16). 
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Figure 16: Analysis of indel mutations at the target site in two different cell populations after magnetic-activated 
cell sorting. A) Cells with an inactivation of the target gene B) Wild type cells 
 
A high rate of indel mutations (95.8%) was ascertained in the knockout cell group but not in 
the wild type population. These results indicate that both MACS and FACS facilitate the 
efficient separation of cell populations with high purity. The viability of cells was higher after 
MACS which was therefore used for all further experiments. Cells from all three mosaic 
foetuses were separated with this method and used for genome sequencing to analyse the 
frequency of off-target mutations caused by CRISPR/Cas9 mediated gene editing.  
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5.3.3. Analysis of off-target mutations 
 
A comparative analysis of edited and non-edited cell populations was performed by WGS at 
mean coverages of 30 times (conducted by Dr. Christine Wurmser, Chair of Animal Breeding, 
TUM). The -Gal- and -Gal+ cell populations of embryos number 5 and six were analysed. 
The amount of DNA that could be isolated from embryo number 2 was not sufficient to establish 
a library for WGS because only 6% of cells were wild type. SNVs and indel mutations were 
identified using three different variant calling algorithms (Lofreq, Strelka and Mutect2 for 
SNVs and in addition Scalpel for Indels). The intersection of three algorithms were considered 
as true SNVs and the intersection of four algorithms as true indel variants.  
WGS analysis revealed a low level of -Gal- cells in the wild type group probably due to false-
negative cell sorting (<5%). PCR amplification was conducted prior to WGS to obtain the 
necessary amount of DNA for library preparation. Therefore, only variants with allele 
frequencies >60% were considered in the analysis to exclude false positive results. In embryo 
number five 65 SNVs and 1 indel mutations (at the target site) and in embryo number six 17 
SNVs and 1 indel mutation (at the target site) were found. The comprehensive data of SNV and 
indel analysis are shown in Appendix 10.1. The amount of SNVs is shown in Figure 17 and 
Indel Mutations are depicted in Figure 18.  
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Figure 17: Comparative analysis of SNVs A) Embryo number 5; B) Embryo number 6; The overlap between all 
three algorithms were considered true SNVs. Only variants with an allele frequency >60% were considered. 
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Figure 18: Comparative analysis of indel mutations A) Embryo number 5; B) Embryo number 6; The overlap 
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All somatic mutations were compared with the 14 most common off-target sites predicted by 
the CC-Top tool (see Table 14) but no sequence alignment was detected. 






























































Table 14: The 14 most common off-target sites predicted by the CC-Top tool. No sequence alignment was detected 
between the somatic mutations and the predicted off-target sites. 
All cell populations were screened for the integration of the plasmid vector. None of the 
alignments with the plasmid sequence was found to be above the sequencing background noise 
(see Figure 19). The plasmid sequence could not be detected in any cell population. 
 
 
Figure 19: Sequence alignment with the plasmid sequence. The plasmid sequence could not be detected in any 
cell population. All alignments are below the background sequencing noise (brown line). Ingenis-956 is the pig 
reference genome.  
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In summary, mosaic foetuses containing edited and non-edited cells were generated by 
intracytoplasmic microinjection of CRISPR/Cas9 vectors targeting the GGTA1 gene into one 
blastomere of in vitro derived porcine two-cell-stage embryos. Embryos were surgically 
transferred into synchronised surrogate pig mothers, one pregnancy was established and aborted on 
day 38. Fourteen foetuses were isolated and 3 of them were identified as mosaic. Edited and non-
edited cell populations within those individuals were separated using magnetic beads, followed by 
WGS. The non-edited cells were used as the control group to distinguish naturally occurring 
mutations from off-target mutations. In embryo number five  65 SNVs and one indel mutation 
were detected and in embryo number six 17 SNVs and one indel mutation at the target site were 
detected. None of the somatic mutations aligned with the predicted off-target sites and no 










The major goal of this work was to evaluate the feasibility, efficiency, and safety of gene editing 
in pigs. Section 6.1 discusses the modification of the FUT1 gene and gene editing as a tool to 
improve animal welfare. The analysis of off-target mutations by two-cell stage microinjection 
is examined in segment 6.2. 
 
6.1. Gene editing as a tool to improve animal welfare 
 
Globalisation, falling prices and increasing demands on animal welfare coupled with novel 
threats for animal health imposed by climate change (heat stress, spread of pathogens) pose new 
challenges for modern livestock production [2]. Animal genetics play a decisive role for animal 
health, but traditional livestock breeding is limited by long breeding cycles and the availability 
of genetic resources [131]. Gene editing could allow us to overcome these bottlenecks by 
facilitating the incorporation of genetic traits from other breeds, related species or laboratory 
findings [46].  
 
6.1.1. Practical implications of gene editing for animal welfare 
 
Due to the lack of germline transmittable embryonic stem cells gene targeting was extremely 
challenging in livestock species in the past [132]. Modern gene editing technology facilitates 
the efficient generation of gene targeted farm animals [133]. In the future gene editing could 
supplement traditional breeding techniques to meet the goal of producing healthier and more 
productive livestock [134]. 
The goal of this project was the establishment and evaluation of methods for the base-specific, 
efficient, and safe modification of the porcine genome by the example of Oedema Disease. We 
were able to precisely and efficiently (>90%) perform the desired G to A base exchange in vitro 
in somatic cells using a CRISPR/Cas9 expression vector and ssDNA repair template. The in 
vivo experiments in porcine zygotes confirmed the efficiency of this approach. Most 
publications describe in vivo targeting efficiencies of about 60-70% [66, 135]. Here, the desired 
FUT1 AA genotype could be confirmed in 93% of parthenotes and 94% of IVF zygotes after 
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microinjection. These results compare favourably to the literature and confirm that base specific 
edits can be performed in vitro and in vivo with high efficiencies. Differences in the 
effectiveness of gene editing at different genomic loci can be explained by chromatin state and 
secondary sgRNA structure [136].  
In the case of the FUT1 gene one single genetic modification mediates Oedema Disease 
resistance. However, many traits of interest are polygenic and require multiple edits 
simultaneously to achieve the desired effect which is technically more challenging [62]. 
Multiplex gene editing can be conducted in one step using multiple sgRNAs, but each edit is a 
separate stochastic event which decreases the likelihood of obtaining all desired modifications 
simultaneously [58, 135]. Therefore, somatic cell nuclear transfer (SCNT) is the method of 
choice for multiplex gene editing because it allows for the selection and screening of donor 
cells prior to the generation of animals to ensure they carry the desired set of modifications 
[137]. 
Analysis of wild type embryos revealed that the FUT1-AA genotype appeared at a much higher 
frequency within the local pig population than previously known. Based on comprehensive 
literature research the favourable allele was expected to be prevalent at a frequency of 5-10% 
[39, 46]. Our results and new sequencing data indicate that selection for the favourable FUT1-
AA allele was successful in Deutsches Edelschwein (DE, 44%) but this was not the case in 
German Landrace (DL, 0%) and Piétrain (PI, 7%). These data demonstrate that breeding for 
OD resistance in DE, particularly in Switzerland was successful beyond expectations. A similar 
timeframe of several decades would be necessary to increase the frequency of the desirable 
allele in other breeds (PI, DE) to similar levels. Gene editing has the potential to accelerate this 
process significantly. 
The high frequency at which the FUT1-AA allele was ascertained in slaughterhouse derived 
oocytes (66%) is plausible as they stem from hybrid pigs containing DE genetics (DLxDExPI) 
[138]. The low frequency at which the favourable FUT1 allele occurs in DL and PI pigs makes 
the incorporation of effective selection into standard breeding regimes hard due to the risk of 
inbreeding and associated long-term productivity loss [139]. Genome editing could contribute 
in such circumstances by allowing the introduction of the favourable gene variant into a specific 
breeding population in one generation while keeping other desirable traits unsolicited [131, 
140]. However, a large number of genetically modified founder animals needs to be generated 
to avoid inbreeding and maintain background genetic variation [139]. 
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In the context of disease resistance, a clear distinction must be made between full resistance 
and disease resilience. The generation of pigs resilient to African Swine Fever Virus infection 
by interspecies allele introgression using gene editing is exemplary [141]. Resilient animals 
could act as reservoirs of infection and therefore their use would be prohibited in many 
jurisdictions [46]. However, such animals could be useful in regions where the specific disease 
is endemic. 
One potential risk that gene editing has in common with other disease mitigation strategies such 
as vaccination is the limited shelf life of disease resistance due to the emergence of escape 
mutants [142]. This is especially problematic for pathogens with extremely high mutation rates 
such as RNA viruses like PRRSV [143] but also a justified concern for genetically mediated 
OD resistance. 
Gene editing has the potential to solve many problems encountered in traditional livestock 
breeding but with any new technology, caution should be taken prior to its large-scale 
application. Tracking and registration of gene edited animals are difficult because the changes 
are footprint-free [144]. However, unlike genetically modified crops gene edited farm animals 
are easier to contain which prevents the dispersal of contaminated altered genes from 
genetically engineered organisms to natural organisms [145]. 
All current gene editing technologies (ZFNs, TALENs, CRISPR/Cas9) have the potential to 
induce off-target mutations in the genome [93, 98, 146]. These can harm the health of 
individuals which is a major obstacle for therapeutic gene editing [147]. Therefore, is 
imperative to carry out a thorough phenotypic and genotypic characterisation of gene edited 
animals. Another concern is the possibility of unwanted integration of the gene editing vector 
into the genome.  This risk can be eliminated by using Cas9 mRNA or protein together with the 
gRNA instead of a gene editing vector encoding both components [62]. 
Low public acceptance and the regulatory framework are the biggest obstacles for gene editing 
in livestock species. Approval of genetically modified animals is handled differently in each 
jurisdiction and depends on legislation which is currently still in its early stages [148]. Some 
jurisdictions such as Argentinia or Brazil have ruled that modifications that do not require the 
integration of new genetic material into the genome are exempt from regulation [149]. In the 
US gene edited livestock are regulated as drugs. The approval of the first gene edited animal 
for sale on the open market (AquAdvantage® salmon) took 25 years [150]. The recent approval 
of GalSafe® GGTA1 knockout pigs by the FDA might pave the way for other gene edited 
livestock [151]. The European Court of Justice ruled that organisms derived by gene editing are 
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subject to the same regulations as genetically modified organisms (GMOs) [149]. Barring a 
change in legislation, this makes the approval of genetically modified livestock for sale in the 
European Union unlikely for the foreseeable future [149]. 
 
6.1.2. Ethical considerations 
 
Certain genetic modifications align animal welfare and economic interests because they 
improve animal health and increase productivity simultaneously. Disease resistant animals such 
as PRRSV resistant pigs [152], Avian Leukosis Virus resistant chickens [153, 154], or 
tuberculosis resilient cattle are exemplary [155]. Pigs resistant to Oedema Disease fall into this 
“win-win” category because the disease-resistant genotype which occurs naturally within the 
pig population is not associated with any adverse phenotypic consequences [39]. Genetic 
modifications that allow animals to avoid undergoing painful procedures such as dehorning 
[156] or castration [157] also fall into this “win-win” category.  
Gene editing can also be used to improve livestock performance, but this often contradicts 
animal welfare. One example is the generation of cattle [140], goats [158], and pigs [159] with 
dramatically elevated muscle growth caused by the inactivation of the myostatin gene. These 
animals suffer from gastric ulcers, high stress sensitivity, and lameness due to abnormal leg 
development which highlights the limitations of this approach [160].  
The principle for the conservation of welfare formulated by the philosopher Bernard Rollin in 
1995 states: “Any animals that are genetically modified through the use of genetic technology, 
for purposes other than research, should be no worse off, in terms of suffering, than the parent 
stock was prior to genetic alterations” [161]. Both, gene editing and traditional animal breeding 
have the potential to create phenotypes that result in suffering and lead to health problems e.g., 
fast-growing broilers [162]. Increasing performance at the expense of animal welfare is highly 
questionable from an ethical and veterinary perspective. [163].  
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In summary, gene editing facilitates the efficient and precise modification of the genome in 
livestock species. However, many relevant traits are polygenic which requires multiplex gene 
editing. Genetically mediated disease resistance has similar weak spots as other disease 
mitigation strategies i.e., mutation of pathogens. Gene editing to improve animal welfare is 
ethical if the animals are no worse off in terms of suffering than prior to the genetic alteration.  
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6.2. Off-target analysis by two-cell stage microinjection 
 
Traditional methods for off-target analysis are based on screening of in silico predicted off-
target sites or whole genome sequencing. These approaches fail to distinguish between single 
nucleotide variants (SNVs) that occur in each individual during embryogenesis and off-target 
mutations caused by gene editing technology [117, 164]. Our goal was to detect off-target 
mutations by editing one blastomere of two-cell stage pig embryos followed by whole genome 
sequencing. Comparison of sequencing data between progeny cells of edited and non-edited 
blastomeres allows the differentiation between SNVs and off-target mutations in vivo.  
 
This approach termed genome-wide off-target analysis by two-cell embryo injection (GOTI) 
was developed in mice [12]. The original study was conducted in Ai9 mice (B6.Cg-Gt ROSA 
26Sortm9, CAG-td-Tomato) with conditional tdTomato expression silenced by a floxed “stop” 
cassette. The conditional mutation was activated by co-injection of Cre mRNA together with 
the components of various gene editors to achieve tdTomato expression and later facilitate cell 
separation by FACS. A similar reporter pig line with constitutive expression of a red 
fluorescence marker (Tomato) and Cre-inducible expression of a green fluorescence marker 
(eGFP) is available but no pregnancies could be obtained using sperm with this genotype for 
IVF. The GGTA1 gene was chosen as an alternative target for gene editing because the presence 
or absence of the -Gal surface glycosylation facilitates the precise and unequivocal separation 
of cell populations [14]. Another advantage of this approach is that it does not depend on the 
availability of transgenic reporter lines with conditional expression of fluorescent proteins and 
can be performed in species where such animals are not available. 
The fact that 14 foetuses were obtained suggests high viability of embryos after microinjection 
at the two-cell-stage. All embryos were injected with the gene targeting vector but still, eight 
wild type embryos were obtained. This means that either no gene editing had taken place, the 
blastomere was damaged beyond repair during microinjection, or simply did not contribute to 
the embryo proper [165]. The homozygous inactivation of the GGTA1 gene in three embryos 
implies that only the edited blastomere contributed to the embryo proper. In the three mosaic 
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Two different methods were established for the separation of the different cell populations. 
Both magnetic- and fluorescence assisted cell sorting resulted in the separation of -Gal 
positive and negative cells with high purities (>95%). However, consistent with the literature 
the magnetic approach resulted in higher viability of cells after separation [166].  
There are many gene editing tools and nucleases and new ones are developed at a rapid pace 
[167]. A comprehensive safety evaluation including off-target analysis is mandatory prior to 
the application of each new technology [10]. In the future, advances in gene editing technology 
could improve the specificity and safety of gene editing to facilitate its large scale agricultural 
and therapeutic application [11]. The required level of comprehensiveness of off-target analysis 
depends on the intended application of gene editing.  
For research, the primary concern is whether off-target mutations might confound the 
interpretation of biological phenotypes. This can be ruled out by performing control 
experiments such as using multiple sgRNAs to introduce the same mutation [117]. For clinical 
applications of gene editing safety is the predominant concern because even low mutation 
frequencies can lead to detrimental outcomes. Therefore, the most sensitive, comprehensive, 
and unbiased approach should be used to identify all potential off-target sites [168]. Multiple 
redundant approaches are required to analyse off-target effects for this purpose because a fully 
comprehensive and sensitive method currently does not exist [117]. Off-target mutations are a 
concern for the use of gene editing as a novel breeding tool in farm animals as well. The large-
scale utilisation of gene edited animals with adverse phenotypes caused by off-target mutations 
would have far reaching economic consequences. However, over time such mutations would 
likely disappear by genetic drift or be selected against if they result in adverse phenotypic 
consequences [131]. 
The original study revealed that cytosine base editors generate a substantial number of off-
target mutations in mice but for the CRISPR/Cas system off-target events occur at a frequency 
close to the spontaneous mutation rate (on average 12 SNVs per embryo) [12]. These findings 
are consistent with a similar study conducted in rice plants [169].  
We detected 17 and 65 SNVs per embryo which is within the rate of approximately 60-80 
mutations that naturally occur during embryogenesis [170]. These findings agree with a clone-
based study in cattle that compared the mutation frequency and spectra in bovine cells and 
calves cloned from these edited and non-edited cell lines [171]. The study showed that gene 
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edited cells and calves did not carry a higher mutation load than the non-edited control group 
[171]. 
A recent study revealed that even monozygotic twins differ on average by 5 early 
developmental mutations and that 15% of them have a high number of mutations specific to 
only one twin [172]. A median number of 48 postzygotic mutations specific to only one twin 
was detected in high coverage (152x) pairs [172]. This indicates that while cells from the same 
embryo are the best possible control group available there is still the possibility of genomic 
sequence differences between them [172]. 
Another possible explanation is the short period of in vitro cultivation which was necessary to 
remove cell detritus prior to sorting. In vitro cultivation is known to cause somatic mutations 
in mammalian cells at a rate ranging from 2x10-6 to 0.7x10-7 [173, 174]. Due to population 
averaging these can be removed from the analysis by only considering SNVs with high allele 
frequencies. However, amplification of a next generation sequencing library is performed by 
PCR [175]. This is a potential source of mutations because even high fidelity polymerases have 
a certain error rate [176]. This step can introduce artefacts into sequencing libraries by 
amplifying natural mutations and increases their allele frequency [175]. Therefore, only 
variants with an allele frequency >60% were considered in the analysis. 
PCR-free WGS avoids these drawbacks and is the method of choice for future GOTI 
experiments [177]. However, because the required, larger amount of sample DNA was not 
available only traditional PCR based WGS could be performed here. No sequence similarity 
was observed between the adjacent sequences of the SNVs and the predicted off-target sites. 
Indel mutations were only observed at the target site. Therefore, it is likely that some SNVs 
observed here are artefacts caused by a combination of in vitro cultivation or spontaneous 
mutation in conjunction with PCR amplification rather than true off target mutations. 
 
In summary, we provide first proof of principle that GOTI is a useful method to analyse the off-
target effects caused by gene editing tools in livestock without the interference of SNVs. The 
rate of mutations detected here is close to the natural mutation rate and none of the SNVS 
aligned with the predicted off-target sites. Therefore, it is highly likely that they are artefacts 
caused by PCR amplification during library generation. PCR-free WGS technology could 
facilitate a more precise evaluation of off-target mutations in the future. A final statement 
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regarding the frequency of off-target mutations cannot be made because even cells from the 
same embryo have certain genomic differences.  
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Efficiency and safety of gene editing in pigs: Evaluated in an experimental and in a 
disease relevant model 
 
In this thesis, the feasibility, efficiency, and safety of gene editing technology were analysed in 
the pig. Gene editing has the potential to complement traditional breeding techniques and help 
improve animal health and welfare. However, concerns regarding the safety of this new 
technology prevent its application outside of research.  
Because pigs are physiologically very similar to humans and play an important role in 
agriculture, they are a suitable model to analyse the potential and risks of gene editing for 
applications in agriculture and potential therapeutic applications in patients. In this study the 
FUT1 gene which mediates resistance to Oedema disease was edited in vitro in somatic cells 
and in vivo in porcine embryos. The desired base specific G>A nucleotide exchange at position 
307 was performed precisely and efficiently using CRISPR/Cas9 expression vectors in 
combination with ssDNA repair templates. The generation of OD resistant animals by GE was 
not planned within the scope of this project. 
 
The second part of this project focused on the investigation of off-target mutations caused by 
CRISPR/Cas9 technology, the most widely used GE tool. One blastomere of porcine two-cell-
stage embryos was microinjected with CRISPR/Cas9 expression vectors to generate mosaic 
foetuses. The edited and non-edited cell populations from two mosaic foetuses were separated 
and analysed by whole genome sequencing. This approach facilitates the differentiation 
between natural mutations that occur during embryogenesis and off-target mutations caused by 
gene editing technology. The frequency of SNVs in embryos edited by CRISPR/Cas9 was 
higher than expected but within the spontaneous mutation rate. Because none of the mutations 
aligned with the predicted off-target sites they are likely artefacts caused by PCR amplification 
during library generation. A more precise evaluation of off-target mutations could be obtained 
by avoiding the cell culture step and by utilising PCR-free Next Generation Sequencing 
technology. Cells from the same embryo are the best possible control group but a final 
distinction between off-target effects and natural mutations remains difficult because even these 
have certain genomic differences. 
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Effizienz und Sicherheit der Genom-Editierung beim Schwein: Evaluierung in einem 
experimentellen und einem krankheitsrelevanten Model 
 
In dieser Arbeit wurde die Machbarkeit, Effizienz und Sicherheit der Genom-Editierung beim 
Schwein analysiert. Genom Editierung könnte in Zukunft traditionelle Züchtungsmethoden 
ergänzen und somit zur Verbesserung der Tiergesundheit und des Tierwohls beitragen. 
Allerdings verhindern Zweifel bezüglich der Sicherheit dieser neuen Technologie ihre 
Anwendung außerhalb der Forschung. 
Schweine sind Menschen physiologisch sehr ähnlich und spielen eine wichtige Rolle in der 
Landwirtschaft. Deshalb sind sie ein geeignetes Model, um die potenziellen Risiken der 
Genom-Editierung vor einer möglichen Anwendung in der Landwirtschaft oder Humanmedizin 
zu erforschen. Hier wurde das FUT1 Gen, welches die Resistenz gegenüber der Ödemkrankheit 
vermittelt in vitro in somatischen Zellen und in vivo in Schweine Embryos editiert. Der 
erwünschte G>A Basenaustausch an Position 307 konnte präzise und effizient durchgeführt 
werden. Hierzu wurden CRISPR/Cas9 Expressionsvektoren in Verbindung mit 
einzelsträngigen DNA-Reparaturvorlagen verwendet. Die Generierung gegen Ödemkrankheit 
resistenter Tiere mittels Genom-Editierung war im Rahmen dieses Projektes nicht vorgesehen. 
Der zweite Teil dieses Projektes beschreibt die Erforschung von Off-Target Mutationen durch 
CRISPR/Cas9, das am häufigsten Verwendete Werkzeug für die Genom-Editierung. Eine 
Blastomere eines Zwei-Zell Embryos wurde mit CRISPR/Cas9 Expressionsvektoren 
mikroinjiziert, um mosaike Föten zu erzeugen. Die editierten und nicht editierten 
Zellpopulationen wurden separiert und durch Sequenzierung des gesamten Genoms analysiert. 
Diese Vorgehensweise erlaubt eine Abgrenzung zwischen natürlichen Mutationen, welche 
während der Embryogenese entstehen und jenen, welche durch die Genom-Editierung 
verursacht werden. Die Rate an Polymorphismen in den editierten Embryos war höher als 
erwartet, lag aber innerhalb der spontanen Mutationsrate. Keine der Mutationen stimmte mit 
den vorhergesagten off-target Sequenzen überein. Vermutlich handelte es sich hierbei um 
Artefakte, welche durch die PCR Amplifikation zur Erstellung der Sequenzierungsbibliothek 
verursacht wurden.  
82 
8. ZUSAMMENFASSUNG  
 
 
Eine präzisere Evaluierung von Off-Target Mutationen könnte in Zukunft durch Vermeidung 
des Zellkultur Schrittes und durch Verwendung PCR-freier Sequenzierungstechnologie erreicht 
werden. Zellen vom selben Embryo stellen die bestmögliche Kontrollgruppe dar, doch selbst 
diese weisen gewisse genomische Unterschiede auf. Deshalb bleibt eine klare Abgrenzung 
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10.1. Comprehensive data of Indel and SNV analysis 
 
10.1.1. Embryo number five 
 






























































































































































































































































































































































































































































































10.1.2. Embryo number six 
 
CONTRAST VAR_ID CHROM POS REF ALT VAR_TYPE 
6WT_6KO 1_96821088 1 96821088 C T SNV 
6WT_6KO 1_96821093 1 96821093 C T SNV 
6WT_6KO 1_221995969 1 221995969 C T SNV 
6WT_6KO 3_114440106 3 114440106 A G SNV 
6WT_6KO 4_11510992 4 11510992 A G SNV 
6WT_6KO 5_46279560 5 46279560 A G SNV 
6WT_6KO 5_52027092 5 52027092 T C SNV 
6WT_6KO 8_124861724 8 124861724 C T SNV 
6WT_6KO 9_5106971 9 5106971 T C SNV 
6WT_6KO 11_47175839 11 47175839 G A SNV 
6WT_6KO 13_16612136 13 16612136 A G SNV 
6WT_6KO 13_91140310 13 91140310 A G SNV 
6WT_6KO 14_15975979 14 15975979 A G SNV 
6WT_6KO 14_35527918 14 35527918 A G SNV 
6WT_6KO 15_44297475 15 44297475 C T SNV 
6WT_6KO 15_125543798 15 125543798 C T SNV 
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